REVIEW article

Front. Immunol., 29 April 2026

Sec. Inflammation

Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1806445

The oral - X axis: from periodontal dysbiosis to systemic disease

  • 1. Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

  • 2. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Abstract

Chronic oral inflammatory diseases, particularly periodontitis, are increasingly recognized as important contributors to the onset and progression of systemic disorders. Accumulating epidemiological, clinical, and mechanistic evidence indicates that the oral cavity is not an isolated organ, but rather a critical hub and early window for systemic disease development. Through microbial translocation, chronic low-grade inflammation, immune dysregulation, oxidative stress, and epigenetic reprogramming, oral diseases engage in bidirectional communication with distant organs.We conceptualize this integrated network as the “oral-X axis, “ encompassing the oral-cardiovascular, oral-metabolic, oral–respiratory, oral–gastrointestinal, oral-oncologic, oral-immune, oral–brain, and other systemic axes. At the core of these interactions lies periodontitis-associated microbial dysbiosis dominated by key pathogens such as Porphyromonas gingivalis, Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans. The ensuing inflammatory response compromises periodontal barrier integrity, facilitating the dissemination of bacteria, virulence factors, and inflammatory mediators into the systemic circulation. These processes promote endothelial dysfunction, insulin resistance, breakdown of immune tolerance, neuroinflammation, and the formation of pro-tumorigenic microenvironments, thereby mechanistically linking oral inflammation to a broad spectrum of systemic diseases. This review systematically summarizes the current evidence supporting the oral-X axis, with a particular focus on epidemiological associations and underlying molecular and cellular mechanisms. In addition, we discuss periodontal interventions and oral microbiome modulation as potential strategies for the prevention and treatment of systemic diseases. A deeper understanding of the oral-X axis may provide novel insights into integrated oral–systemic healthcare and precision medicine.

1 Introduction

Chronic periodontitis (CP) is a chronic inflammatory disease driven by the interaction between dental plaque-associated microorganisms and host immune responses. Sustained inflammation and immune activation lead to the progressive destruction of periodontal supporting tissues and alveolar bone resorption (1). Epidemiological studies indicate that periodontitis is the sixth most prevalent disease worldwide, with its global burden continuing to increase due to population aging and the persistence of major risk factors. It is estimated that more than 10% of adults globally are affected by severe periodontal disease (PD) (2).

An expanding body of evidence has demonstrated strong associations between oral diseases and a wide range of systemic disorders, including diabetes mellitus, inflammatory bowel disease, colorectal cancer, Parkinson’s disease, Alzheimer’s disease, atherosclerosis, adverse pregnancy outcomes, thyroid cancer, rheumatoid arthritis, and systemic lupus erythematosus (3–9). Shared pathogenic pathways underlying the interplay between oral and systemic diseases include chronic low-grade inflammation, microbial dysbiosis, immune dysregulation, oxidative stress, and metabolic imbalance. In addition, periodontal inflammation facilitates the systemic dissemination of oral pathogens, virulence factors, and inflammatory mediators. Conversely, systemic diseases may exacerbate periodontal tissue destruction by disrupting immune and metabolic homeostasis, highlighting the bidirectional relationship between oral health and systemic health.

Accordingly, we propose the concept of the “oral-X axis” to describe the bidirectional biological communication between the oral cavity and multiple organ systems. Within this framework, the oral cavity functions as a major microbial reservoir and inflammatory source, linking oral health to systemic pathophysiology through multiple dissemination routes and signaling pathways. This review aims to systematically summarize current research on the oral-X axis, integrating epidemiological evidence with underlying molecular and cellular mechanisms, and to discuss the clinical implications of oral interventions and modulation strategies in the prevention and management of systemic diseases.

2 Current research situation of “oral-X” axis

2.1 Oral-cardiovascular axis

Cardiovascular disease (CVD) remains the leading cause of non-communicable mortality worldwide, accounting for approximately one-third of all global deaths (10). Epidemiological studies indicate that the prevalence of both hypertension and periodontitis increases in parallel with advancing age, and that the two conditions share common demographic and behavioral risk factors, including older age, male sex, smoking, overweight status, and metabolic disturbances (3, 11–13). Genetic studies further suggest that interactions between polymorphisms in endothelin-1 (ET-1), angiotensin-converting enzyme (ACE), and pro-inflammatory cytokines (e.g., TNF-β) may increase susceptibility to periodontitis (14). Conversely, individuals with moderate to severe periodontitis exhibit a 20-50% higher risk of hypertension compared with periodontally healthy individuals (15).

Atherosclerosis (AS), the pathological basis of most forms of CVD, shares substantial overlap with periodontitis in terms of inflammatory and oxidative mechanisms, including elevated C-reactive protein levels, cytokine imbalance, and enhanced oxidative stress (16–21). Epidemiological evidence demonstrates that periodontitis is associated with an approximately 20% increased risk of atherosclerosis, while longitudinal studies further suggest that periodontal disease may elevate the future risk of atherosclerotic cardiovascular events (22–24).

2.2 Oral-respiratory axis

An increasing body of evidence supports a close association between periodontitis and respiratory diseases, particularly pneumonia. Patients with pulmonary disorders often exhibit poorer periodontal status, characterized by higher periodontal indices and an increased risk of oral infection (25). Clinical studies have demonstrated that individuals with moderate to severe periodontitis have an approximately fourfold higher risk of developing community-acquired pneumonia (CAP) compared with periodontally healthy individuals (26).

Notably, a two-sample Mendelian randomization study conducted in East Asian populations provided evidence for a potential causal relationship between specific oral microbial genera and respiratory tract infections, further revealing species-specific effects on bronchitis, pneumonia, sinusitis, and bronchiectasis (27). Long-term observational studies have also shown that periodontitis is associated with increased pneumonia-related mortality in vulnerable populations, such as patients undergoing hemodialysis (26, 28, 29).

2.3 Oral-metabolic axis

Diabetes mellitus is a global metabolic disorder affecting more than 440 million individuals worldwide and is characterized by chronic hyperglycemia and systemic inflammation (30). Diabetes markedly increases the risk of periodontitis, with the prevalence of periodontal disease in diabetic patients being approximately threefold higher than in non-diabetic individuals (31, 32). Conversely, periodontitis exacerbates glycemic dysregulation, establishing a bidirectional pathogenic relationship. Clinical and experimental evidence indicates that periodontal therapy can significantly reduce glycated hemoglobin levels, systemic inflammatory burden, and vascular dysfunction, with effects comparable to those achieved by the addition of an antidiabetic medication (33–35). A recent cross-sectional clinical study further demonstrated that, among patients who were unaware of their diabetic status, chairside HbA1c testing during periodontal treatment can detect previously unrecognized hyperglycemia. This finding indicates that periodontitis is not only closely associated with metabolic diseases but can also serve to monitor early disturbances in glucose metabolism (36).

Pregnancy-related metabolic disturbances are also closely associated with periodontal disease. Severe periodontitis has been independently linked to an increased risk of gestational diabetes mellitus (GDM) (37–42). Obesity further amplifies periodontal inflammation during pregnancy, suggesting that preconception weight management and periodontal intervention may help attenuate systemic inflammatory activation (43).

In addition, polycystic ovary syndrome (PCOS), a heterogeneous endocrine–metabolic disorder, has been consistently associated with periodontal inflammation and oxidative stress (44–51). Meta-analyses have demonstrated a bidirectional relationship, whereby periodontitis increases the risk of PCOS by 46%, and PCOS increases the risk of periodontitis by 28% (51). Hypothyroidism and obesity have also been reported to be associated with periodontitis, sharing common features of chronic low-grade inflammation and increased periodontal susceptibility (52–62).

2.4 Oral-gastrointestinal axis

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is frequently accompanied by oral manifestations and an increased prevalence of periodontitis (63–79). Meta-analyses have demonstrated that both the prevalence and severity of periodontitis are significantly higher in patients with IBD than in healthy controls, suggesting the involvement of shared immune-mediated mechanisms between these conditions (79–82).

Chronic liver diseases (CLD), encompassing viral hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cirrhosis, have also been associated with periodontal disease (83–86). Patients with NAFLD exhibit a higher prevalence of periodontitis, and interventional studies indicate that periodontal therapy can reduce serum liver enzyme levels as well as systemic antibody titers against periodontal pathogens (87–89). Moreover, liver cirrhosis and post–liver transplantation status are associated with exacerbated periodontal inflammation and an increased incidence of peri-implant complications, underscoring the bidirectional interplay between oral and hepatic health (90–94).

2.5 Oral-oncologic axis

Periodontitis is increasingly recognized as a potential risk factor for multiple malignancies, particularly cancers of the digestive tract. Oral squamous cell carcinoma has been shown to be associated with periodontal inflammation and dysbiosis, with periodontal pathogens frequently enriched within tumor tissues (95–99). Epidemiological studies further support associations between periodontitis and cancers of the esophagus, stomach, colorectum, liver (hepatocellular carcinoma), and pancreas, which remain statistically significant after adjustment for major confounding factors such as smoking, alcohol consumption, and diabetes (100–114).

In addition, associations between periodontitis and lung, thyroid, and breast cancers have been reported; however, the strength and consistency of evidence vary substantially across different cancer types (115–124). Overall, chronic periodontal inflammation and microbial dysbiosis may contribute to tumor initiation and progression through systemic inflammatory and immune-mediated pathways, although causal relationships have yet to be definitively established.

2.6 Oral-immune axis

Periodontitis shares fundamental mechanisms of chronic inflammation and immune dysregulation with immune-mediated diseases. Among these, the association between rheumatoid arthritis (RA) and periodontitis is particularly prominent, with up to 75% of patients with RA exhibiting moderate to severe periodontal disease (125–129). Meta-analyses indicate that periodontitis increases the risk of RA by approximately 69%, and that RA disease severity is positively correlated with the extent of periodontal destruction.

Similarly, systemic lupus erythematosus (SLE) and Graves’ disease have been associated with periodontal inflammation, alterations in the oral microbiota, and elevated levels of pro-inflammatory cytokines, further supporting a contributory role of periodontal disease in systemic immune activation (130–135).

2.7 Oral-brain axis

Neurodegenerative and neuropsychiatric disorders have emerged as a critical component of the oral–X axis. Chronic periodontitis has been associated with an increased risk of Alzheimer’s disease, with elevated antibodies against periodontal pathogens detectable several years prior to cognitive decline (136–139). Parkinson’s disease has also been linked to periodontal inflammation, and longitudinal studies suggest that sustained periodontal care may slow disease progression (140–143). Furthermore, periodontitis has been identified as an independent risk factor for depression, potentially mediated through systemic inflammation and behavioral pathways (144–148).

2.8 Oral-other axis

Periodontal inflammation in pregnant women has been associated with adverse pregnancy outcomes (149), with approximately 40% of expectant mothers exhibiting clinical signs of periodontitis (150). Evidence indicates that periodontitis may increase the risk of preterm birth (151), spontaneous abortion (152), low birth weight (153), preeclampsia (154), fetal growth restriction (155), and gestational diabetes mellitus (156).

Chronic kidney disease (CKD) is defined as structural or functional abnormalities of the kidney persisting for more than three months (157). Numerous population-based studies have demonstrated a close association between periodontitis and CKD. In a cross-sectional study of middle-aged adults (n = 5, 537), Kshirsagar et al. reported that individuals with chronic periodontitis exhibited an estimated glomerular filtration rate decline approximately twice that of periodontally healthy individuals, with kidney damage severity positively correlating with periodontitis severity (158). A longitudinal study involving 1, 486 participants confirmed that, after adjusting for age, sex, diabetes, hypertension, and smoking, periodontal pocket depth remained independently associated with CKD progression (159). Another cohort study of 761 men found that the prevalence of CKD in participants with severe periodontitis was 2.04-fold higher than in controls (160). These findings suggest that periodontal inflammation may contribute to renal impairment via persistent systemic inflammation and immune dysregulation.

Prostatitis is clinically characterized by urinary symptoms and genital pain, with a prevalence of up to 25% (161). Epidemiological evidence indicates that periodontitis is associated with an increased risk of benign prostatic hyperplasia (BPH), with odds ratios ranging from 1.50 to 1.68 after adjusting for clinical and demographic confounders (162, 163). Prostate cancer (PC) is the second most common malignancy among men worldwide (164). Cohort studies across different regions have consistently shown that chronic periodontitis modestly but significantly increases PC risk, with relative risk elevations ranging from 14% to 73%, depending on study design and follow-up duration (165–167).

Osteoporosis (OP) is a systemic skeletal disorder characterized by decreased bone mass and increased fracture risk, predominantly affecting postmenopausal women and the elderly (168). Accumulating evidence suggests a bidirectional relationship between periodontitis and bone loss. In a study of 5, 383 participants, Tak et al. reported a significant correlation between the number of remaining teeth in men and bone mineral density (BMD) at the lumbar spine and proximal femur, with individuals possessing fewer than 10 teeth exhibiting markedly lower BMD (169). Other studies have shown that osteoporosis increases the risk of periodontitis by more than twofold (170), while hormone replacement therapy combined with vitamin D and calcium supplementation can mitigate periodontal disease severity in osteoporotic women (171). Conversely, severe periodontitis has been associated with increased osteoporosis incidence (172); a large cohort study reported that periodontitis was an independent risk factor for osteoporosis in women (HR = 1.22, 95% CI: 1.01–1.48), whereas no such association was observed in men (173). These findings support the notion that periodontal disease and skeletal disorders share common inflammatory and bone remodeling pathways (Table 1, Figure 1).

Table 1

Oral–X axisAssociated systemic diseasesKey epidemiological/clinical evidenceRepresentative mechanisms
Oral–cardiovascular axisHypertension, atherosclerosis, cardiovascular disease (CVD)Periodontitis is associated with a 20–50% increased risk of hypertension and approximately a 20% higher risk of atherosclerosis; both conditions share common demographic characteristics and genetic susceptibilitySystemic inflammation, endothelial dysfunction, oxidative stress, imbalance of inflammatory mediators
Oral–respiratory axisPneumonia, Bronchitis, Sinusitis, BronchiectasisModerate-to-severe periodontitis is associated with an approximately fourfold increased risk of community-acquired pneumonia; Mendelian randomization studies support a causal role of oral microorganismsAspiration of oral pathogens, airway colonization, impaired host defense
Oral–metabolic axisDiabetes, Gestational diabetes mellitus (GDM), Obesity, Polycystic Ovary Syndrome (PCOS), Thyroid diseasesThe prevalence of periodontitis is approximately threefold higher in patients with diabetes; periodontal therapy significantly reduces HbA1c levels, with an effect size comparable to adjunctive antidiabetic medication; a bidirectional association with PCOS has been reportedLow-grade systemic inflammation, insulin resistance, oxidative stress, endocrine–immune interactions
Oral–gut axisInflammatory bowel disease (IBD), Non-alcoholic fatty liver disease (NAFLD), Chronic liver disease, Liver cirrhosisPatients with IBD exhibit increased prevalence and severity of periodontitis; periodontal treatment has been shown to improve liver enzyme levels and immunological parameters in patients with NAFLDMucosal immune dysregulation, microbial translocation, oral–gut microbiota crosstalk
Oral–cancer axisOral cancer, Esophageal cancer, Gastric cancer, Colorectal cancer, Pancreatic cancer, Liver cancerAfter adjustment for smoking and alcohol consumption, periodontitis remains significantly associated with an increased risk of gastrointestinal malignancies; periodontal pathogens are enriched in tumor tissuesChronic inflammation, immune modulation, microbe-mediated carcinogenesis
Oral–immune axisRheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Graves’ diseasePeriodontitis is associated with an approximately 69% increased risk of RA; disease activity correlates with the severity of periodontal tissue destructionMolecular mimicry, autoantibody production, trained immunity
Oral–brain axisAlzheimer’s disease, Parkinson’s disease, DepressionElevated antibody levels against periodontal pathogens precede cognitive decline; periodontal intervention may slow the progression of Parkinson’s diseaseNeuroinflammation, systemic cytokine signaling, blood–brain barrier dysfunction
Oral–pregnancy axisAdverse pregnancy outcomesPeriodontitis is associated with increased risks of preterm birth, miscarriage, low birth weight, preeclampsia, and GDMInflammatory overflow, placental immune activation
Oral–kidney axisChronic kidney disease (CKD)Periodontitis is associated with an approximately twofold increased risk of estimated glomerular filtration rate (eGFR) decline and accelerated CKD progressionPersistent systemic inflammation, immune dysregulation
Oral–prostate axisBenign prostatic hyperplasia (BPH), Prostate cancer (PC)Periodontitis is associated with an increased risk of BPH (OR 1.50–1.68) and a modestly elevated risk of prostate cancerChronic inflammation, immune modulation
Oral–bone metabolism axisOsteoporosisA bidirectional association between periodontitis and reduced bone mass has been reported, with notable sex-specific differencesInflammatory bone remodeling, dysregulated osteoimmune signaling

Epidemiological evidence and mechanistic overview of the oral–X axis and systemic diseases.

CVD, cardiovascular disease; CAP, community-acquired pneumonia; GDM, gestational diabetes mellitus; PCOS, polycystic ovary syndrome; IBD, inflammatory bowel disease; NAFLD, non-alcoholic fatty liver disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; BPH, benign prostatic hyperplasia; PC, prostate cancer; OR, odds ratio.

Figure 1

3 Pathophysiological mechanisms of the oral-X axis

3.1 Oral microbial dysbiosis as an initiating factor

The oral cavity is one of the four major microbial reservoirs in the human body, and disruption of its homeostasis is central to the development and progression of periodontitis. Key periodontal pathogens, including Porphyromonas gingivalis, Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans, produce virulence factors such as lipopolysaccharides (LPS), gingipains, leukotoxins, outer membrane vesicles (OMVs), and adhesins (e.g., FadA), which continuously compromise the local epithelial barrier and induce inflammation. This facilitates systemic dissemination of microbial components, contributing to multisystem diseases. For example, the Cnm+ serotype of Streptococcus mutans, which exhibits enhanced extracellular matrix (ECM) binding, has been associated with infective endocarditis, cerebrovascular disease, and IgA nephropathy (174–182). Fusobacterium nucleatum is enriched in oral squamous cell carcinoma tissues and increases with tumor progression (183, 184). Subgingival colonization by Tannerella forsythia, Campylobacter rectus, Prevotella intermedia, Prevotella melaninogenica, and P. gingivalis during pregnancy has been linked to preterm birth and low birth weight (185–188). The abundance of A. actinomycetemcomitans, P. gingivalis, T. forsythia, and Treponema denticola is significantly associated with hypertension, and P. gingivalis antigens can exacerbate angiotensin II–induced hypertensive responses (189–192). Increased oral pathogen load and reduced microbial diversity in patients with systemic lupus erythematosus, chronic kidney disease, and esophageal cancer further indicate the systemic impact of oral dysbiosis (132, 193–196).

3.2 Ectopic colonization of oral pathogens

Ectopic colonization of oral pathogens refers to the dissemination of oral microorganisms to distant organs via swallowing, inhalation, transient bacteremia, or immune cell–mediated transport, and constitutes an important pathological basis of the oral–systemic disease axis (197–199).

3.2.1 Gastrointestinal route

Approximately 1.5 L of saliva enters the digestive tract daily. When gastrointestinal barrier integrity is compromised, P. gingivalis, F. nucleatum, Klebsiella spp., and other pathogens can survive and colonize the gut, disrupting microbial homeostasis, reducing short-chain fatty acid production, impairing epithelial barriers, and increasing the risk of inflammatory bowel disease (IBD) and colorectal cancer (200–202). A. actinomycetemcomitans and P. gingivalis have been associated with chronic atrophic gastritis and gastric precancerous lesions (203). In animal models, P. gingivalis can migrate via the pancreatic duct and promote pancreatic tumorigenesis (204). Oral-origin F. nucleatum is enriched in colorectal cancer tissues, driving pro-tumor inflammation and remodeling the immune microenvironment (205–216).

3.2.2 Respiratory route

Periodontal pathogens can be aspirated into the lower respiratory tract, inducing pneumonia and exacerbating chronic obstructive pulmonary disease (COPD). Dental plaque and periodontal pockets serve as reservoirs for Streptococcus pneumoniae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (25, 217–222). Typical periodontal bacteria have been detected in airway samples of patients during acute exacerbations of severe COPD, indicating oral–respiratory microbial crosstalk (217).

3.2.3 Hematogenous dissemination

Ulcerated periodontal pockets provide a direct pathway for bacteria and endotoxins to enter the circulation. Recurrent transient bacteremia in animal models accelerates coronary and aortic atherosclerosis, supporting a causal link between periodontal infection and cardiovascular disease (19, 223–225).

3.2.4 Placental and genitourinary route

High-throughput sequencing has shown that placental microbiota more closely resembles the oral microbiome than the gut or vaginal microbiomes. F. nucleatum, P. gingivalis, and C. rectus have been detected in placental tissues and amniotic fluid, inducing inflammatory cascades, impairing placental function, and contributing to adverse pregnancy outcomes (226–238). Oral pathogens may also reach the reproductive tract via the gastrointestinal–reproductive axis or sexual transmission, further disrupting local microbial homeostasis (239, 240).

3.2.5 Neural route

Postmortem brain tissues from Alzheimer’s disease patients have revealed components of P. gingivalis LPS, Treponema spp., and Chlamydia pneumoniae. Animal studies have similarly detected P. gingivalis in mouse brains, suggesting its ability to cross the blood–brain barrier and participate in neurodegenerative processes (241–245).

3.2.6 Urogenital route

Studies have detected periodontal pathogens such as T. denticola, P. gingivalis, and F. nucleatum in subgingival plaque, prostatic secretions, and prostate cancer tissues of patients with chronic periodontitis, chronic prostatitis, and benign prostatic hyperplasia, supporting the involvement of ectopic oral colonization in urogenital pathology (246, 247).

3.2.7 Immune cell-mediated transport

Periodontal pathogens can also persist within macrophages and neutrophils, exploiting an immune cell-mediated “Trojan horse” mechanism to disseminate systemically (248).

3.3 Inflammatory overflow

Periodontitis is a chronic inflammatory disease driven by dysbiosis, characterized by sustained immune activation and the release of substantial inflammatory mediators. Patients exhibit persistently elevated levels of circulating CRP, IL-1β, IL-6, and TNF-α, resulting in low-grade systemic inflammation. This state serves as the “common soil” for various systemic chronic diseases (249–251).

3.3.1 Metabolic abnormalities

A significant synergistic amplification effect exists between periodontitis and obesity. In obese patients with chronic periodontitis, the proportion of Tannerella forsythia in the subgingival biofilm increases with rising BMI (252). Furthermore, obese women with periodontitis demonstrate a significantly higher detection rate of Porphyromonas gingivalis in the gingival sulcus compared to non-obese periodontitis patients (253). Additionally, obesity-related metabolic abnormalities, such as insulin resistance, decreased insulin sensitivity, and dyslipidemia are considered critical risk factors for the onset and progression of periodontal disease. The degree of insulin resistance is closely correlated with clinical parameters such as periodontal attachment loss, probing depth, and bleeding index (254). Patients with combined obesity and insulin resistance exhibit significantly greater periodontitis severity than those with obesity alone (255). The underlying mechanism involves inflammation and oxidative stress, which impair insulin sensitivity and lead to the accumulation of glycolysis products in the gingival crevicular fluid (GCF), thereby exacerbating periodontal tissue destruction (255–257). In patients with metabolic syndrome (MetS), gingival crevicular fluid (GCF) biomarkers exhibit distinct patterns. Aggrecan levels decrease with increasing severity of periodontitis, reflecting local tissue degradation. In contrast, IL-8 and MMP-8 levels are elevated in patients with diabetes independently of periodontal status, indicating systemic metabolic inflammation. These patterns support the use of GCF analysis as a non-invasive tool for probing oral-systemic interactions and suggest that, in populations with metabolic dysfunction, periodontal therapy and glycemic control may exert synergistic beneficial effects on the GCF inflammatory profile (258).

3.3.2 Cardiovascular disease

Periodontitis is an independent, non-traditional risk factor for cardiovascular disease (CVD), a prevalent association that is particularly significant in adults under 45 and middle-aged women (259, 260). Low-grade systemic inflammation is considered a crucial mechanistic link between periodontitis and atherosclerosis. Circulating inflammatory mediators and periodontal pathogen endotoxins can activate vascular endothelial cells, inducing endothelial dysfunction, one of the initiating steps of atherosclerosis (261). Within this inflammatory environment, leukocyte adhesion, smooth muscle cell migration, and lipid deposition are accelerated, promoting arterial plaque formation. Concurrently, the upregulation of matrix metalloproteinases (MMPs) weakens the stability of the fibrous cap, increasing the risk of plaque rupture and thrombosis, which may precipitate myocardial infarction or stroke. High-sensitivity CRP (hs-CRP), as a comprehensive marker of systemic inflammatory burden, has been proposed as a vital reference indicator for future periodontal grading and risk assessment (262).

3.3.3 Kidney injury

Patients with chronic kidney disease (CKD) universally exhibit a micro-inflammatory state, characterized by elevated levels of pro-inflammatory markers such as IL-6, CRP, TNF-α, and fibrinogen (263). Studies indicate that serum CRP levels are significantly elevated in periodontitis patients, and circulating periodontal pathogens and their byproducts can directly injure renal endothelial cells. Consequently, periodontitis, as a source of chronic inflammation, may promote the onset and progression of CKD (264). Furthermore, periodontitis is closely associated with endothelial dysfunction. Bacteria and inflammatory mediators disseminate continuously via the bloodstream to distal organs like the kidneys, disrupting microvascular endothelial homeostasis and aggravating renal injury, which further supports the risk role of periodontitis in CKD pathogenesis (265).

3.3.4 Neuroinflammation

Systemic inflammation triggered by periodontitis can activate microglia in the central nervous system via increased blood–brain barrier (BBB) permeability or vagus nerve signaling, thereby inducing neuroinflammatory responses. Activated microglia release neurotoxic mediators, leading to neuronal injury and synaptic dysfunction—processes closely implicated in the pathogenesis of depression and neurodegenerative diseases (266–268). Moreover, periodontitis-associated inflammatory cytokines (e.g., IL-1β, TNF-α) can interfere with the metabolism of neurotransmitters such as serotonin and dopamine, resulting in mood dysregulation and an increased risk of depression (265, 269, 270).

3.3.5 Adverse pregnancy outcomes

Periodontal pathogens can disrupt epithelial and endothelial barriers, inducing local placental inflammation, abnormal remodeling of spiral arteries, and placental functional defects, which may lead to adverse pregnancy outcomes (271–278). Additionally, inflammatory mediators (such as TNF-α, IL-6, and PGE2) can directly stimulate uterine myometrial contraction, promoting the premature rupture of membranes (PROM) and preterm birth; alternatively, they may cross the placental barrier to induce fetal immune-inflammatory responses, causing damage to fetal tissues and organs (279–288).

3.4 Oxidative stress

Oxidative stress is recognized as a crucial pathophysiological bridge linking localized periodontal inflammation to systemic diseases. During the onset and progression of periodontitis, neutrophils undergo a “respiratory burst” to eliminate subgingival pathogens, generating a large amount of reactive oxygen species (ROS). When local ROS production exceeds the clearance capacity of the body’s antioxidant system, excess ROS can enter the systemic circulation, triggering a systemic oxidative stress response. This leads to lipid peroxidation, protein modification, and DNA damage, thereby contributing to the pathogenesis of various systemic diseases.

Clinical studies have shown that the level of oxidative stress in patients with type 2 diabetes mellitus (T2DM) and periodontitis is significantly higher than in individuals with periodontitis alone or in healthy individuals, with a marked decrease in plasma small-molecule antioxidant capacity (289). Pradeep et al. (290) reported that levels of 4-hydroxy-2-nonenal (4-HNE), a terminal product of lipid peroxidation, in both gingival crevicular fluid and serum, were significantly higher in patients with T2DM and chronic periodontitis compared to patients with periodontitis alone.

Oxidative stress also serves as a significant shared mechanism between periodontitis and polycystic ovary syndrome (PCOS). Chronic periodontitis can lead to elevated levels of DNA oxidative damage markers in the serum and saliva of PCOS patients, alongside a reduction in total serum antioxidant status (291).

When periodontitis coexists with atherosclerosis, the body’s oxidative load is significantly higher than in either condition alone. Clinical evidence indicates that serum total oxidant status (TOS) and oxidative stress index (OSI) are markedly elevated in periodontitis patients with atherosclerosis, while antioxidant capacity is further compromised (292).

In recent years, mitochondrial dysfunction has been identified as an important cytological basis for oxidative stress in periodontitis. Gingival tissues and gingival fibroblasts from patients with chronic periodontitis commonly exhibit mitochondrial structural abnormalities, decreased membrane potential, reduced oxygen consumption rate, and a decreased copy number of mitochondrial DNA. Stimulation with P. gingivalis LPS can induce healthy gingival fibroblasts to prematurely generate mitochondrial ROS, triggering the release of IL-1β, IL-6, and TNF-α. This amplified inflammatory cascade can be effectively blocked by mitochondria-targeted antioxidants or by enhancing endogenous antioxidant enzyme activity (293, 294).

3.5 Immune dysregulation and the pro-tumorigenic microenvironment

Oral chronic inflammation can remodel host immunity, leading to a prolonged imbalance in immune homeostasis. Through pathological immune activation, immune suppression/exhaustion, and immune cell recruitment and polarization, it significantly increases susceptibility to autoimmune diseases, chronic inflammatory diseases, and malignancies.

3.5.1 Autoimmune reactions and immune activation

Multiple studies have indicated that Porphyromonas gingivalis (P. gingivalis) infection often precedes the onset of rheumatoid arthritis (RA), and patients with aggressive periodontitis exhibit significantly elevated anti-citrullinated protein antibody (ACPA) titers (295–297). The autoimmune reaction to citrullinated proteins is a fundamental basis for RA pathogenesis. P. gingivalis is currently the only known oral pathogen capable of producing peptidylarginine deiminase (PAD). It can break self-tolerance via “molecular mimicry, “ inducing citrullination of various host proteins, thereby triggering the generation of ACPAs. These ACPAs cross-react with synovial antigens, driving synovitis and joint destruction in RA (298, 299).

3.5.2 Systemic humoral immune activation

Patients with periodontitis show significantly elevated local and systemic levels of IgA/IgG. Moreover, antibody titers against periodontal pathogens are positively correlated with antibodies against malondialdehyde-acetaldehyde modified LDL, which is closely associated with the severity of atherosclerosis (18, 300–303). Systemic IgG levels are significantly increased in mice infected with Filifactor alocis (304). The abundance of Anaeroglobus geminatus positively correlates with probing depth and the anti-phosphatidylcholine IgG response, suggesting its involvement in driving systemic humoral immune activation during periodontitis (132, 299).

3.5.3 Tumor immune remodeling driven by periodontitis

3.5.3.1 Immune suppression and T cell dysfunction

Periodontal pathogens have been detected in tissues of oral squamous cell carcinoma (OSCC), esophageal cancer, pancreatic cancer, and colorectal cancer (CRC). Long-term chronic antigen stimulation may lead to T cell exhaustion or immune tolerance, weakening the body’s immune surveillance against other pathogens or tumor cells. Clinical studies show that PD-1/PD-L1 expression in the peripheral blood and tumor microenvironment of periodontitis patients is significantly higher than in healthy controls, and this phenomenon can be partially reversed by initial periodontal therapy (305). Fecal microbiota transplantation experiments further confirmed that the periodontitis-associated microbiota can downregulate IFN-γ+ CD8+ T cells in mice, accelerating CRC development (306). In CRC samples, Fusobacterium nucleatum (F. nucleatum) DNA content is negatively correlated with CD3+ T cell density. F. nucleatum exerts immunosuppressive activity by inhibiting human T cell immune function, thereby promoting cancer cell proliferation (307). Furthermore, P. gingivalis can suppress host immune functions, exploit the complement system, and disrupt host immune defense responses to protect itself from attacks by humoral and cellular immune systems (308).

3.5.3.2 Immune cell recruitment and polarization

Periodontal pathogens drive the polarization of tumor-associated macrophages towards the immunosuppressive M2 phenotype via chemotactic cytokines, further shaping an immune-evasive tumor microenvironment (309). Research by Tan et al. (204) demonstrated that P. gingivalis activates the CXCL1-CXCR2 axis to recruit tumor-associated neutrophils, promoting pancreatic ductal adenocarcinoma progression. Narikiyo et al. (310) found increased expression of IL-8 and GRO-α in a cell model infected with Streptococcus anginosus, activating the recruitment and activation of neutrophils and monocytes, thereby promoting esophageal cancer progression. Other researchers, through KEGG enrichment analysis, found that F. nucleatum promotes invasive behavior of cancer cells by activating the chemokine CCL20 (311).

3.6 Signaling pathways linking periodontal pathogens to systemic diseases

Periodontal pathogens induce systemic pathological alterations by activating host pattern recognition receptor (PRR)-mediated signaling cascades or by directly modulating intracellular pathways via virulence factors. These signals converge on immune activation, metabolic dysregulation, bone homeostasis imbalance, and cell survival programs, thereby extending localized periodontal inflammation to distant organs.

3.6.1 Immune recognition and inflammation initiation

Periodontal pathogens and their components (particularly LPS) are primarily sensed by Toll-like receptors (TLRs). Porphyromonas gingivalis (P. gingivalis) LPS activates TLR2 and TLR4, which, via the MyD88-dependent pathway, activate the IKK complex, leading to IκB degradation and NF-κB nuclear translocation. This subsequently induces the transcription of key pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α (206, 309). Animal studies have shown that P. gingivalis infection exacerbates oxidative stress and systemic inflammation via the NF-κB/iNOS signaling pathway, significantly accelerating atherosclerotic plaque formation (312). A hyperglycemic environment can upregulate TLR2 expression in gingival fibroblasts, amplifying the inflammatory response, which partially explains the aggravated periodontal destruction in diabetes (313). This pathway serves as a core molecular link between periodontitis and chronic inflammatory diseases like atherosclerosis and diabetes.

3.6.2 Bone homeostasis and metabolic imbalance: RANKL/OPG and AGE-RAGE axes

Periodontal bone resorption is regulated by the balance between RANKL and OPG. In patients with type 2 diabetes (especially those with HbA1c ≥8.0%), the levels of RANKL and the RANKL/OPG ratio in gingival crevicular fluid are significantly elevated, exacerbating alveolar bone loss (314, 315).

Advanced glycation end products (AGEs) and their receptor (RAGE) signaling do not directly initiate inflammation but promote the recruitment of inflammatory cells and sustained cytokine release (8). In diabetic periodontitis, AGEs activate gingival fibroblasts via the RAGE/NF-κB pathway, upregulating MMP-1 and accelerating connective tissue destruction (316). Pharmacological blockade of the AGE-RAGE signaling pathway can mitigate periodontal inflammation and bone loss in diabetic animal models (317).

3.6.3 Tumor promotion and immune evasion: oncogenic and anti-apoptotic pathways

Periodontal pathogens promote tumorigenesis by remodeling the tumor microenvironment and directly interfering with host cell signaling pathways (Figure 2).

Figure 2

Wnt/β-catenin Signaling: The Fusobacterium nucleatum (F. nucleatum) adhesin FadA binds to epithelial E-cadherin, disrupting cell-cell junctions and activating the Wnt/β-catenin pathway. Nuclear β-catenin induces the transcription of oncogenes such as c-Myc and Cyclin D1, increasing vascular permeability and promoting tumor cell proliferation (318).

Anti-apoptotic and Proliferative Signaling: P. gingivalis enhances cell survival through multiple mechanisms: (1) Activating PI3K/Akt and inhibiting PTEN, leading to the inactivation of the pro-apoptotic protein Bad and upregulation of Bcl-2 (319); (2) Activating JAK1/STAT3, inducing the transcription of anti-apoptotic genes (320); (3) Modulating the miR-21/PDCD4/AP-1 feedback loop, resulting in Cyclin D1 overexpression and accelerated cell cycle progression (321).

Invasion and Metastasis: Gingipains activate PAR2/4, triggering ERK1/2-ETS1, p38/HSP27, and NF-κB signaling pathways. This activates pro-MMP-9 and degrades the extracellular matrix, enhancing the invasion and metastatic potential of oral squamous cell carcinoma (322, 323).

Immune Microenvironment Reprogramming: F. nucleatum Fap2 binds to the inhibitory receptor TIGIT on NK and T cells, directly suppressing cytotoxic activity (324, 325). Both P. gingivalis and F. nucleatum promote the polarization of tumor-associated macrophages towards the immunosuppressive M2 phenotype and upregulate inhibitory molecules such as PD-L1, ultimately impairing CD8+ T cell-mediated anti-tumor immunity (326).

3.6.4 Neurological effects: neuroinflammation and cognitive impairment

Periodontal pathogens influence central nervous system homeostasis via the oral-brain axis. Experimental studies indicate that oral administration of P. gingivalis or its outer membrane vesicles (OMVs) allows entry into the brain, activating microglia. This increases pro-inflammatory cytokine secretion in human microglial clone 3 (HMC3) cells, promoting neuroinflammation and tau protein hyperphosphorylation, thereby further inducing neuroinflammation (327).

3.6.5 Endocrine and vascular dysfunction

P. gingivalis OMVs can inhibit insulin-induced Akt/GSK-3β signaling in hepatocytes, reducing insulin sensitivity and interfering with insulin signaling and glucose metabolism (328). Regarding vascular function, P. gingivalis LPS promotes endothelial-mesenchymal transition through the TGF-β/Smad, ERK/MEK, PI3K, and p38 MAPK pathways, contributing to atherosclerosis (329). Its OMVs also induce vascular smooth muscle cell calcification via the ERK1/2–RUNX2 signaling pathway (330).

3.7 Genetics

Genome-wide association studies (GWAS) of periodontitis have demonstrated that genetic variation is one of the contributing factors to immune dysregulation associated with the disease. Significant genetic overlap has been identified between periodontitis and various bacterial diseases, cardiometabolic disorders, and autoimmune diseases, providing genetic evidence for the “oral-systemic axis.” (331) In patients with metabolic syndrome, host genetic variants, particularly single nucleotide polymorphisms (SNPs) in genes such as RUNX2, CAMTA1, and VDR—are associated with the diversity of the gingival microbiome and the abundance of specific bacteria (e.g., Porphyromonas gingivalis and Streptococcus mutans). These findings suggest that host genetic variations related to systemic metabolic health may indirectly shape the oral microbial community by modulating immune responses, a phenomenon referred to as “genetically driven dysbiosis, “ thereby further influencing the risk of periodontitis and systemic diseases (332).

3.8 Epigenetics

3.8.1 Atherosclerosis and cardiovascular disease

The core mechanism by which periodontitis accelerates atherosclerosis lies in its induction of pro-inflammatory epigenetic reprogramming in monocytes/macrophages. Studies reveal that stimulation with Porphyromonas gingivalis (P. gingivalis) lipopolysaccharide (LPS) or live bacteria can induce lasting alterations in histone modifications at the promoter regions of inflammation-related genes (e.g., TNFA, IL6) in monocytes. These changes include, for example, an increase in H3K4me3 (an activating mark) and a decrease in H3K9me3 (a repressive mark). This modified state can be maintained even after the stimulus is removed, rendering the cells hyperresponsive to subsequent pro-atherogenic stimuli (e.g., ox-LDL), leading to increased production of pro-inflammatory cytokines and accelerating plaque development (333). Animal models confirm that periodontal infection can enhance histone acetylation levels within macrophages of the aortic root plaques in atherosclerosis-prone mice (334).

3.8.2 Type 2 diabetes and insulin resistance

Chronic inflammation is a key driver of insulin resistance, with histone modifications acting as downstream effectors of inflammatory signaling pathways such as NF-κB. Under the combined influence of hyperglycemia and chronic inflammatory factors (e.g., TNF-α), pathways like NF-κB in insulin target tissues (adipose, liver) and immune cells become persistently activated. Activated NF-κB recruits histone acetyltransferases (e.g., p300) to the promoter regions of genes involved in promoting inflammation and gluconeogenesis (e.g., Pck1), resulting in sustained histone acetylation and gene overexpression, forming a “metabolic memory” (335). When periodontitis is concurrent, the persistent systemic inflammatory burden it generates can further exacerbate systemic insulin resistance and metabolic dysregulation. This process is believed to involve an aggravation of the aforementioned epigenetic programming (31).

3.8.3 Rheumatoid arthritis

Periodontitis and RA share an autoimmune inflammatory background, with histone citrullination representing a unique intersection point. The periodontal pathogen P. gingivalis is not only the sole human pathogen known to express PPAD (peptidylarginine deiminase), but its infection can also upregulate the activity of the host’s own PAD enzymes (e.g., in neutrophils). PADs catalyze the citrullination of arginine residues on histones H3 and H4. Citrullinated histones not only alter their own function but can also serve as novel autoantigens recognized by autoantibodies, thereby breaking immune tolerance and contributing to RA pathogenesis (336). This provides direct molecular evidence supporting the concept that “periodontal infection is an environmental trigger for RA.”

3.8.4 Tumor initiation and progression

Systemic inflammation associated with periodontitis may influence the tumor microenvironment via histone modifications. Beyond the classic mechanisms of direct bacterial dissemination and inflammatory mediator spread affecting distal tumorigenesis, epigenetic reprogramming, particularly alterations in histone modifications, is garnering increasing attention. Chronic inflammation itself is a key driver of aberrant epigenetic programming associated with tumors (337). Periodontitis possesses a unique capacity for epigenetic intervention; its major pathogen, P. gingivalis, secretes proteases capable of directly cleaving histones, and microbial metabolites such as butyrate are known histone deacetylase (HDAC) inhibitors (248). Such local interventions may have systemic consequences. Recent research indicates that periodontitis can induce long-term, pro-inflammatory epigenetic reprogramming in bone marrow hematopoietic stem cells (a phenomenon termed ‘trained immunity’), leading to the persistent production of functionally altered myeloid cells (334). These cells, upon entering the circulation, may infiltrate distant tumor sites and, through their abnormal histone modification status and gene expression profiles, contribute to the formation of an immunosuppressive tumor microenvironment. Furthermore, drawing from gut microbiome research, the paradigm where microbial metabolites influence host immunity and cancer by modulating histone modifications has been established (338), suggesting that periodontal dysbiosis may participate in systemic epigenetic regulation via similar pathways.

3.8.5 Post-transcriptional regulation by non-coding RNAs

Non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), play a central role in post-transcriptional gene regulation and serve as crucial mediators linking periodontal inflammation to systemic diseases. Within the inflammatory microenvironment of periodontitis, the circulating and exosomal miRNA profiles undergo significant alterations. These miRNAs can be transported via extracellular vesicles to distant organs, where they modulate insulin sensitivity, metabolic homeostasis, and vascular function, thereby establishing a molecular bridge between periodontitis and the pathologies associated with obesity, diabetes, and hypertension.

Distinct miRNA expression patterns have been observed in individuals with obesity and concomitant periodontitis. Perri et al. reported that in obese periodontitis patients, miR-150, miR-24, and miR-27a were upregulated, while members of the let-7 family and miR-26a-5p were downregulated, suggesting synergistic dysregulation in pathways related to adipogenesis, insulin signaling, and immune activation (339). Notably, there is increased expression of virally derived miRNAs (particularly those encoded by human herpesviruses) in the gingival tissues of obese periodontitis patients. For instance, HHV-8-derived miR-K12-4-3p may indirectly influence periodontal inflammation and metabolic dysfunction by competing with host miRNAs for shared targets or by regulating viral latency and replication (340).

Beyond metabolic diseases, shared miRNA signatures have also been identified between periodontitis and cardiovascular conditions. Rodriguez et al. (341) identified 13 miRNAs associated with both periodontitis and hypertension, including miR-100-5p, miR-21-5p, miR-34a-5p, miR-146a-5p, miR-26b-5p, miR-126-3p, miR-181a-5p, miR-15b-5p, miR-223-5p, miR-16-5p, miR-30a-5p, and miR-17-5p. These miRNAs are predominantly known regulators of endothelial function, vascular inflammation, and smooth muscle cell behavior, highlighting the convergence of post-transcriptional regulatory networks in the periodontal-cardiovascular interplay (Table 2).

Table 2

ncRNA/miRNATargeted pathways or moleculesAssociated systemic diseasesMajor mechanisms of actionReferences
miR-146aIRAK1, TRAF6/NF-κBDiabetes mellitus, systemic inflammationDysregulation of negative feedback control of NF-κB signaling, resulting in imbalanced inflammatory responses and amplification of systemic inflammationPerri R et al, 2012 (339)
miR-150Inflammatory and immune regulatory pathwaysObesity with periodontitisAssociated with immune cell differentiation and metabolic inflammation; upregulation reflects amplification of chronic inflammatory responsesNaqvi A R et al, 2019 (340)
miR-24MAPK/inflammatory signalingObesity, metabolic disordersRegulates inflammation- and lipid metabolism–related pathways, contributing to metabolic–inflammatory crosstalkNaqvi A R et al, 2019 (340)
miR-27aAdipogenesis and insulin signalingObesity, insulin resistanceModulates adipocyte differentiation and energy metabolism, thereby exacerbating metabolic imbalanceNaqvi A R et al, 2019 (340)
let-7 familyInsulin signaling, cell cycle regulationObesity, diabetes mellitusDownregulation leads to reduced insulin sensitivity and enhanced chronic inflammationNaqvi A R et al, 2019 (340)
miR-26a-5pInflammatory and metabolic homeostasis pathwaysObesity, metabolic syndromeDownregulation is associated with disruption of metabolic homeostasis and persistence of inflammatory responsesNaqvi A R et al, 2019 (340)
miR-K12-4-3pHost inflammation-related genesObesity with periodontitisCompetitively targets host genes with cellular miRNAs, regulating viral latency and indirectly modulating inflammation and metabolismPerri R et al, 2012 (339)
miR-21-5pNF-κB, PTENHypertension, cardiovascular diseasesRegulates vascular inflammation and endothelial function, contributing to the development of hypertensionRodriguez N M ea al, 2024 (341)
miR-100-5pmTOR signaling/vascular homeostasisHypertensionAffects vascular smooth muscle cell function and inflammatory responsesRodriguez N M ea al, 2024 (341)
miR-34a-5pCellular senescence and inflammatory pathwaysHypertension, cardiovascular diseasesPromotes endothelial dysfunction and a pro-inflammatory senescent phenotypeRodriguez N M ea al, 2024 (341)
miR-126-3pEndothelial repair and angiogenesisHypertensionA key endothelial-protective miRNA; downregulation indicates impaired vascular homeostasisRodriguez N M ea al, 2024 (341)
miR-223-5pImmune cell activationHypertension, systemic inflammationRegulates inflammatory responses of granulocytes and macrophagesRodriguez N M ea al, 2024 (341)
miR-15b-5p/miR-16-5pCell cycle and inflammatory regulationHypertensionInfluences vascular cell proliferation and inflammatory signalingRodriguez N M ea al, 2024 (341)
miR-17-5p/miR-30a-5pTGF-β/inflammatory pathwaysHypertensionParticipates in vascular remodeling and maintenance of chronic inflammationRodriguez N M ea al, 2024 (341)
miR-181a-5pImmune regulation and metabolic signalingHypertensionModulates immune activation thresholds and affects vascular inflammationRodriguez N M ea al, 2024 (341)
miR-26b-5pMetabolic and inflammatory pathwaysHypertensionAssociated with regulation of metabolic homeostasis and vascular functionRodriguez N M ea al, 2024 (341)

ncRNA-mediated post-transcriptional regulation linking periodontitis to systemic diseases.

4 Treatment

Current research indicates that intensive periodontal therapy can improve both periodontal and systemic conditions by removing subgingival plaque. However, despite interventions such as scaling and root planing procedures, adjunctive antibiotic regimens, and supportive periodontal therapy (SPT), periodontitis remains prone to recurrence. Moreover, long-term use of antibiotics can lead to side effects such as gastrointestinal issues and drug resistance (342–344). Therefore, a holistic approach exploring anti-inflammatory drugs with cross-disease applicability, microbial-targeted and immunomodulatory therapies, and natural compounds may offer more possibilities for treating the comorbidity of periodontitis and systemic diseases (Figure 3).

Figure 3

4.1 Cross-disease therapeutic application of anti-inflammatory drugs

Inflammation is a common pathological basis for periodontitis and many systemic diseases. Drugs with anti-inflammatory properties, particularly antidepressants, have been explored as adjunctive treatments for periodontitis.

For example, the tricyclic antidepressant (TCA) tianeptine, in a rat model of depression (induced by olfactory bulbectomy) combined with periodontitis, not only improved depressive behavior but also significantly reduced periodontal tissue destruction and alveolar bone resorption. Its mechanisms involve stimulating hippocampal neurogenesis, lowering lipopolysaccharide (LPS)-induced pro-inflammatory cytokines (e.g., TNF-α), and increasing the production of anti-inflammatory factors (e.g., TGF-β1 and IL-10), thereby modulating the host’s immune response to bacterial challenge (345).

Another TCA, desipramine, has been shown to reduce alveolar bone loss in rats with experimental periodontitis. Its protective effects are associated with downregulating key inflammatory mediators (IL-1β, inducible nitric oxide synthase, cyclooxygenase-2) in periodontal tissues, as well as inhibiting dendritic cell antigen presentation and T-lymphocyte proliferation—cells that are important regulators of periodontal bone remodeling (346).

Furthermore, the selective serotonin reuptake inhibitor (SSRI) fluoxetine has demonstrated both anti-inflammatory and antidepressant effects. A clinical cross-sectional study found that depression patients receiving fluoxetine treatment had better periodontal clinical parameters (bleeding on probing, clinical attachment loss) compared to non-medicated patients. Animal experiments further indicate that fluoxetine alleviates periodontal inflammation and bone destruction by reducing IL-1β expression in gingival tissues and inhibiting NF-κB transcriptional activity and matrix metalloproteinase-9 (MMP-9) production (347).

4.2 Microbial-targeted and immunomodulatory therapies

Targeted therapies against key periodontal pathogens and the abnormal immune responses they trigger are a current research focus. For instance, developing monoclonal antibodies against virulence factors of specific pathogens has shown efficacy in inhibiting periodontal destruction in experimental periodontitis models (348). Given the central role of dysbiosis, using probiotics, prebiotics, or specific antimicrobial peptides to restore the ecological balance of the oral microbiota is a promising “ecological therapeutic” approach (349).

Moreover, the timely resolution of inflammation is as crucial as its initiation. Research reveals that endogenous pro-resolving mediators (e.g., lipoxins) can not only actively terminate inflammation and clear tissue debris but also enhance mucosal defense, preventing the entry of periodontal pathogens into the bloodstream. This points to a direction for developing novel drugs that mimic or enhance these endogenous pathways (350).

4.3 Therapeutic potential of natural compounds

Natural compounds have garnered significant attention for their multi-target and low-toxicity profile in regulating periodontitis and related systemic diseases.

Curcumin: As one of the most widely studied natural anti-inflammatory agents, curcumin effectively inhibits the cytotoxicity of Porphyromonas gingivalis outer membrane vesicles (OMVs). It dose-dependently reduces OMV-induced secretion of inflammatory cytokines (IL-6, IL-1β, TNF-α) from epithelial cells and inhibits OMV adhesion to and invasion of host cells, thereby protecting tissue integrity (351).

Tanshinone IIA: Studies have found that in an atherosclerosis model with P. gingivalis infection, Tanshinone IIA reduces reactive oxygen species (ROS) generation by downregulating NADPH oxidase (NOX2/4) and inhibits the NF-κB signaling pathway. This ultimately lowers systemic and vascular oxidative stress and inflammation, slowing the progression of atherosclerosis (352).

Anethole: Research by Yoshino N et al. shows that anethole, abundant in fennel, exerts a dual antimicrobial effect by depleting essential nutrient transport proteins (RagA/RagB) of P. gingivalis and inhibiting its protease activity (353).

4.4 Epigenetic regulation: a new perspective with HDAC inhibitors

Recent research has highlighted the critical role of epigenetic modifications in chronic inflammatory diseases. Aberrant hyperactivity of histone deacetylases (HDACs) is associated with persistent inflammation and bone destruction. Therefore, HDAC inhibitors are being explored as an emerging therapeutic strategy.

Cantley MD et al. demonstrated that topical application of broad-spectrum or selective HDAC inhibitors (e.g., butyrate, trichostatin A) in experimental periodontitis models exhibits anti-inflammatory and bone-protective effects. The mechanisms involve restoring antimicrobial peptide expression and promoting M2 macrophage polarization. Notably, HDAC inhibitors (e.g., vorinostat) are already clinical drugs for certain hematological malignancies and have shown efficacy in models of autoimmune diseases and atherosclerosis (354).

Treatment with MS-275 significantly reduced local accumulation of immune cells and mRNA levels of representative pro-inflammatory molecules in prostate tissue. It increased the percentage of Foxp3+ CD4+ Treg cells in lymph nodes and their proportion among peripheral blood CD4+ cells. In vitro studies indicated that MS-275 could induce a relative increase in ED2+ macrophages and shift macrophage polarization from the classical M1 phenotype to the anti-inflammatory M2 phenotype (355).

Furthermore, butyrate, an HDAC inhibitor produced by gut microbiota through dietary fiber fermentation, has been shown to alleviate systemic inflammation and improve metabolic health (248).

5 Conclusion and future perspective

Mounting evidence supports the concept of the oral cavity as a critical hub and sentinel for systemic health, rather than an isolated anatomical site. Within the framework of the “oral-X axis, “ this review systematically integrates epidemiological, microbiological, immunological, and mechanistic studies to demonstrate the interplay between oral chronic inflammation and systemic diseases.

Mechanistically, periodontitis represents a source of sustained microbial and inflammatory burden. Initiated by pathogen-dominated oral dysbiosis, it triggers a cascade of events including inflammatory responses, epithelial barrier disruption, endotoxemia, oxidative stress, and immune reprogramming. Beyond direct bacteremia, oral microbes disseminate to distant organs via ectopic colonization through routes such as the gastrointestinal tract, respiratory tract, placental circulation, and immune cell-mediated “Trojan horse” mechanisms. Critically, persistent low-grade inflammation and trained immunity may imprint long-term epigenetic and functional changes in innate immune cells. This provides a mechanistic basis for the chronic, self-perpetuating nature of oral-systemic disease interactions, even after local microbial control.

From a systemic perspective, the oral-X axis should be viewed as a dynamic, bidirectional network where oral inflammation not only exacerbates systemic disease susceptibility but is itself shaped by systemic metabolic, immune, and hormonal disturbances. This mutual reinforcement may partly explain the frequent comorbidity of periodontitis with multiple conditions and the often-limited efficacy of single-organ therapeutic approaches. Reconceptualizing periodontitis as a systemic inflammatory amplifier rather than a localized infection reshapes its role in precision medicine and chronic disease management.

Despite substantial progress, several critical gaps remain. Most current evidence is correlative, and causal inference requires well-designed prospective studies, interventional trials, and integrated multi-omics analyses. Furthermore, microbial heterogeneity across populations, disease stages, and host genetic backgrounds complicates the identification of universal pathogenic signatures. Standardization of periodontal phenotyping and the integration of functional microbial and host immune readouts are essential for advancing the field.

From a translational viewpoint, the oral-X axis offers an evidence base for early intervention and risk stratification. A clinical study found that periodontitis is independently associated with concentric left ventricular remodeling, suggesting that cardiovascular evaluation should be considered for patients with chronic periodontitis, particularly those with concomitant metabolic syndrome (356). Periodontal status and oral microbial signatures may serve as convenient biomarkers for systemic disease risk assessment. Moreover, growing clinical evidence suggests that intensive periodontal therapy and targeted modulation of the oral-gut-immune axis can attenuate systemic inflammation and improve outcomes in specific systemic diseases. Future therapeutic strategies may move beyond mechanical debridement to include host modulators, microbiome-based interventions, and natural bioactive compounds aimed at restoring immune homeostasis rather than merely eradicating pathogens.

In summary, redefining oral health as an integral component of systemic disease prevention and management carries profound implications for both clinical practice and public health. Interdisciplinary collaboration among dentistry, internal medicine, immunology, and systems biology will be crucial for translating mechanistic insights from the oral-X axis into personalized and preventive healthcare strategies.

Statements

Author contributions

WJ: Writing – original draft, Writing – review & editing. LT: Data curation, Writing – review & editing, Writing – original draft. JY: Writing – review & editing, Writing – original draft, Formal analysis. XH: Writing – original draft, Investigation, Writing – review & editing. WG: Writing – original draft, Writing – review & editing, Project administration. HA: Software, Writing – review & editing, Writing – original draft. YZ: Writing – original draft, Writing – review & editing, Funding acquisition, Supervision. ZJ: Writing – review & editing, Funding acquisition, Writing – original draft, Supervision.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This study was supported by Sichuan Natural Science Foundation Project (2026NSFSC0492), Sichuan Natural Science Foundation Project (2025ZNSFSC0625), Special subject of scientific research of traditional Chinese medicine of Sichuan Provincial Administration of Traditional Chinese Medicine (2024MS557), and Chengdu University of Traditional Chinese Medicine 2024 Joint Innovation Fund (WXLH202402019).

Acknowledgments

The authors would like to thank the editors and reviewers for their valuable comments and suggestions. The authors acknowledge the use of BioRender.com for the creation of schematic figures.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    KwonTHLamsterIBLevinL. Current concepts in the management of periodontitis. Int Dental J. (2021) 71:462–76. doi: 10.1111/idj.12630. PMID:

  • 2

    FrenckenJESharmaPStenhouseLGreenDLavertyD. Global epidemiology of dental caries and severe periodontitis–a comprehensive review. J Clin Periodontology. (2017) 44:S94–S105. doi: 10.1111/jcpe.12677. PMID:

  • 3

    Del PintoRPietropaoliDMunoz-AguileraEet al. Periodontitis and hypertension: is the association causal? High Blood Pressure Cardiovasc Prev. (2020) 27:281–9. doi: 10.1007/s40292-020-00392-z. PMID:

  • 4

    SonnenscheinSKMeyleJ. Local inflammatory reactions in patients with diabetes and periodontitis. Periodontology 2000. (2015) 69:221–54. doi: 10.1111/prd.12089. PMID:

  • 5

    Márquez-ArricoCFSilvestreFJFernández-ReyesMLopez-DomenechSHermenejildoJ. Gingival inflammation and leukocyte–endothelium cell interactions in women with polycystic ovary syndrome. J Periodontology. (2025) 96:478–89. doi: 10.1002/JPER.24-0148. PMID:

  • 6

    YanBRenFShangWGongX. Transcriptomic analysis reveals genetic cross-talk between periodontitis and hypothyroidism. Dis Markers. (2022) 2022:5736394. doi: 10.1155/2022/5736394. PMID:

  • 7

    GravesDTCorrêaJDSilvaTA. The oral microbiota is modified by systemic diseases. J Dent Res. (2019) 98:148–56. doi: 10.1177/0022034518805739. PMID:

  • 8

    CasamassimoPS. Relationships between oral and systemic health. Pediatr Clinics North America. (2000) 47:1149–57. doi: 10.1016/S0031-3955(05)70261-3. PMID:

  • 9

    WarnakulasuriyaSRamos-GarcíaPGonzález-MolesMÁ. Oral lichen planus and systemic diseases. J Dent Res. (2026), 00220345251385966. doi: 10.1177/00220345251385966. PMID:

  • 10

    PiepoliMFHoesAWAgewallSAlbusCBrotonsCCatapanoALet al. European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. (2016) 37:2315–81. doi: 10.1714/2729.27821. PMID:

  • 11

    ArboledaSVargasMLosadaSPintoA. Review of obesity and periodontitis: an epidemiological view. Br Dent J. (2019) 227:235–9. doi: 10.1038/s41415-019-0611-1. PMID:

  • 12

    HaytacMCOzcelikOMariottiA. Periodontal disease in men. Periodontology 2000. (2013) 61:252–65. doi: 10.1111/j.1600-0757.2011.00410.x. PMID:

  • 13

    WilliamsBManciaGSpieringWRoseiEAAziziM. 2018 ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. (2018) 39:3021–104. doi: 10.1714/3026.30245. PMID:

  • 14

    HolláLIFassmannAVaškůAZnojilVVaněkJVáchaJ. Interactions of lymphotoxin α (TNF-β), angiotensin-converting enzyme (ACE), and endothelin-1 (ET-1) gene polymorphisms in adult periodontitis. J Periodontology. (2001) 72:85–9. doi: 10.1902/jop.2001.72.1.85. PMID:

  • 15

    Muñoz AguileraESuvanJButiJCzesnikiewicz-GuzikMBarbosa RibeiroAOrlandiMet al. Periodontitis is associated with hypertension: a systematic review and meta-analysis. Cardiovasc Res. (2020) 116:28–39. doi: 10.1093/cvr/cvz201. PMID:

  • 16

    PriyamvaraADeyAKBandyopadhyayDKatikineniVZaghlolR. Periodontal inflammation and the risk of cardiovascular disease. Curr Atheroscl Rep. (2020) 22:28–34. doi: 10.1007/s11883-020-00848-6. PMID:

  • 17

    HerreraDMolinaABuhlinKKlingeB. Periodontal diseases and association with atherosclerotic disease. Periodontology 2000. (2020) 83:66–89. doi: 10.1111/prd.12302. PMID:

  • 18

    SchenkeinHAPapapanouPNGencoRSanzM. Mechanisms underlying the association between periodontitis and atherosclerotic disease. Periodontology 2000. (2020) 83:90–106. doi: 10.1111/prd.12304. PMID:

  • 19

    FriedewaldVEKornmanKSBeckJDGencoRGoldfineA. The American Journal of Cardiology and Journal of Periodontology editors’ consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontology. (2009) 80:1021–32. doi: 10.1902/jop.2009.097001

  • 20

    HigashiYGotoCHidakaTSogaJNakamuraSFujiiYet al. Oral infection-inflammatory pathway, periodontitis, is a risk factor for endothelial dysfunction in patients with coronary artery disease. Atherosclerosis. (2009) 206:604–10. doi: 10.1016/j.atherosclerosis.2009.03.037. PMID:

  • 21

    SchenkeinHALoosBG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. J Periodontol. (2013) 84:51–69. doi: 10.1111/jcpe.12060. PMID:

  • 22

    ChistiakovDAOrekhovANBobryshevYV. Links between atherosclerotic and periodontal disease. Exp Mol Pathol. (2016) 100:220–35. doi: 10.1016/j.yexmp.2016.01.006. PMID:

  • 23

    SanzMDel CastilloAMJepsenSGonzalez-JuanateyJRD’AiutoF. Periodontitis and cardiovascular diseases:consensus report. Glob Heart. (2020) 15:268–88. doi: 10.1111/jcpe.13189. PMID:

  • 24

    ChoDHSongISChoiJGwonJG. Risk of peripheral arterial disease in patients with periodontitis:a nationwide, population- based.matched cohort study. Atherosclerosis. (2020) 297:96–101. doi: 10.1016/j.atherosclerosis.2020.02.012. PMID:

  • 25

    KellyNEl KarimI. Periodontitis may be associated with respiratory diseases such as asthma, COPD, and pneumonia. J Evidence-Based Dental Pract. (2020) 20:101498. doi: 10.1016/j.jebdp.2020.101498. PMID:

  • 26

    IwasakiMTaylorGWAwanoSYoshidaAKataokaS. Periodontal disease and pneumonia mortality in haemodialysis patients: a 7‐year cohort study. J Clin Periodontology. (2018) 45:38–45. doi: 10.1111/jcpe.12828. PMID:

  • 27

    HeJMaoNLyuWZhouSZhangY. Association between oral microbiome and five types of respiratory infections: a two-sample Mendelian randomization study in east Asian population. Front Microbiol. (2024) 15:1392473. doi: 10.3389/fmicb.2024.1392473. PMID:

  • 28

    RastogiTChowdharyZKrishnaMKMehrotraSMohanR. Prevalence of periodontitis in patients with pulmonary disease: a cross-sectional survey in the industrial district of India. J Indian Soc Periodontology. (2019) 23:269–74. doi: 10.4103/jisp.jisp_435_18. PMID:

  • 29

    BenedykMMydelPMDelaleuNPlazaKGawronK. Gingipains: critical factors in the development of aspiration pneumonia caused by Porphyromonas gingivalis. J Innate Immun. (2016) 8:185–98. doi: 10.1159/000441724. PMID:

  • 30

    LovicDPiperidouAZografouIGrassosHPittarasAManolisA. The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol. (2020) 18:104–9. doi: 10.2174/15701611otc46njamtcvy. PMID:

  • 31

    PreshawPMAlbaALHerreraDJepsenSKonstantinidisA. Periodontitis and diabetes: a two-way relationship. Diabetologia. (2012) 55:21–31. doi: 10.1007/s00125-011-2342-y. PMID:

  • 32

    MealeyBLOatesTW. Diabetes mellitus and periodontal diseases. J Periodontology. (2006) 77:1289–303. doi: 10.1111/j.1601-5037.2006.00214.x. PMID:

  • 33

    XavierACVSilvaINCostaFOCorrêaDS. Periodontal status in children and adolescents with type 1 diabetes mellitus. Arq Bras Endocrinol Metab. (2009) 53:348–54. doi: 10.5114/pedm.2020.93249. PMID:

  • 34

    D’AiutoFGkraniasNBhowruthDKhanTOrlandiM. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. (2018) 6:954–65. doi: 10.1016/S2213-8587(18)30038-X. PMID:

  • 35

    SugiyamaSTakahashiSTokutomiFYoshidaAKobayashiK. Gingival vascular functions are altered in type 2 diabetes mellitus model and/or periodontitis model. J Clin Biochem Nutr. (2012) 51:108–13. doi: 10.3164/jcbn.11-103. PMID:

  • 36

    IdeMMainasGKansagraNAl-ZaeimIAngRNOwenDRet al. Association between HbA1c chairside values and periodontitis. J Dentistry. (2026) 167:106563. doi: 10.1016/j.jdent.2026.106563. PMID:

  • 37

    MariottiA. Sex steroid hormones and cell dynamics in the periodontium. Crit Rev Oral Biol Med. (1994) 5:27–53. doi: 10.1177/10454411940050010201. PMID:

  • 38

    YaoHXuDZhuZWangG. Gestational diabetes mellitus increases the detection rate and the number of oral bacteria in pregnant women. Medicine. (2019) 98:e14903. doi: 10.1097/MD.0000000000014903. PMID:

  • 39

    ChokwiriyachitADasanayakeAPSuwannarongWHormdeeDSumanontaG. Periodontitis and gestational diabetes mellitus in non‐smoking females. J Periodontology. (2013) 84:857–62. doi: 10.1902/jop.2012.120344. PMID:

  • 40

    KumarASharmaDSVermaMLambaAKGuptaMM. Association between periodontal disease and gestational diabetes mellitus—a prospective cohort study. J Clin Periodontology. (2018) 45:920–31. doi: 10.1111/jcpe.12902. PMID:

  • 41

    JiangHXiongX. Periodontitis may be associated with gestational diabetes mellitus but not affirmatively. J Evidence Based Dental Pract. (2016) 16:121–3. doi: 10.1016/j.jebdp.2016.06.001. PMID:

  • 42

    Esteves LimaRPCyrinoRMde Carvalho DutraBOliveira da SilveiraJMartinsCC. Association between periodontitis and gestational diabetes mellitus: systematic review and meta‐analysis. J Periodontology. (2016) 87:48–57. doi: 10.1902/jop.2015.150311. PMID:

  • 43

    Foratori-JuniorGAMissioALTOrenhaESde Carvalho Sales-PeresSH. Systemic condition, periodontal status, and quality of life in obese women during pregnancy and after delivery. Int Dental J. (2021) 71:420–8. doi: 10.1016/j.identj.2020.12.012. PMID:

  • 44

    WangFPanJWuYZhuYHardimanPQuF. American, European, and Chinese practice guidelines or consensuses of polycystic ovary syndrome: a comparative analysis. J Zhejiang University-Science B. (2018) 19:354–63. doi: 10.1631/jzus.B1700074. PMID:

  • 45

    LiznevaDSuturinaLWalkerWBraktaSGavrilova-JordanL. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility Sterility. (2016) 106:6–15. doi: 10.1016/j.fertnstert.2016.05.003. PMID:

  • 46

    KellesarianSVMalignaggiVRKellesarianTVAl-KheraifAAAlwageetMM. Association between periodontal disease and polycystic ovary syndrome: a systematic review. Int J Impotence Res. (2017) 29:89–95. doi: 10.1038/ijir.2017.7. PMID:

  • 47

    DursunEAkalınFAGüncüGNCinarNAksoyDY. Periodontal disease in polycystic ovary syndrome. Fertility Sterility. (2011) 95:320–3. doi: 10.1016/j.fertnstert.2010.07.1052. PMID:

  • 48

    PorwalSTewariSSharmaRKSinghalSRNarulaSC. Periodontal status and highsensitivity c-reactive protein levels in polycystic ovary syndrome with and without medical treatment. J Periodontology. (2014) 85:1380–9. doi: 10.1902/jop.2014.130756. PMID:

  • 49

    TongCWangYHYuHCChangYC. Increased risk of polycystic ovary syndrome in Taiwanese women with chronic periodontitis: a nationwide population-based retrospective cohort study. J Women’s Health. (2019) 28:1436–41. doi: 10.1089/jwh.2018.7648. PMID:

  • 50

    DharumanSKumarSABalajiSKVishwanathUParameshwariRP. Evaluation of levels of advanced oxidative protein products in patients with polycystic ovary syndrome with and without chronic periodontitis: A cross-sectional study. Int J Fertility Sterility. (2022) 16:55. doi: 10.22074/IJFS.2021.522861.1073. PMID:

  • 51

    MaChadoVEscaldaCProençaLMendesJJBotelhoJ. Is there a bidirectional association between polycystic ovarian syndrome and periodontitis? A systematic review and meta-analysis. J Clin Med. (2020) 9:1961. doi: 10.3390/jcm9061961. PMID:

  • 52

    ChakerLBiancoACJonklaasJPeetersRP. Hypothyroidism. Lancet. (2017) 390:1550–62. doi: 10.1016/S0140-6736(17)30703-1. PMID:

  • 53

    YerkeLLevineMCohenR. MON -616 potential relationship between hypothyroidism and periodontal disease severty. J Endocr Soc. (2019) 3:MON–616. doi: 10.1210/js.2019-mon-616. PMID:

  • 54

    WangMT. Investigation on oral health awareness and periodontal status of patients with hypothyroidism. China: Kunming Medical University (2024). doi: 10.27202/d.cnki.gkmyc.2024.001603

  • 55

    De Porras‐CarriqueTRamos‐GarcíaPAguilar‐DiosdadoMWarnakulasuriyaSGonzález-MolesMÁ. Autoimmune disorders in oral lichen planus: A systematic review and meta‐analysis. Oral Dis. (2023) 29:1382–94. doi: 10.1111/odi.14127. PMID:

  • 56

    World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. (2000) 894:i–xii, 1–253.

  • 57

    NishidaNTanakaMHayashiNNagataHTakeshitaT. Determination of smoking and obesity as periodontitis risks using the classification and regression tree method. J Periodontology. (2005) 76:923–8. doi: 10.1902/jop.2005.76.6.923. PMID:

  • 58

    Al‐ZahraniMSBissadaNFBorawskiEA. Obesity and periodontal disease in young, middle‐aged, and older adults. J Periodontology. (2003) 74:610–5. doi: 10.1038/sj.bdj.4810597. PMID:

  • 59

    ChaffeeBWWestonSJ. Association between chronic periodontal disease and obesity: a systematic review and meta‐analysis. J Periodontology. (2010) 81:1708–24. doi: 10.1902/jop.2010.100321. PMID:

  • 60

    SaxlinTYlöstaloPSuominen-TaipaleLMannistoSKnuuttilaM. Association between periodontal infection and obesity: results of the Health 2000 Survey. J Clin Periodontology. (2011) 38:236–42. doi: 10.1111/j.1600-051X.2010.01677.x. PMID:

  • 61

    MoritaIOkamotoYYoshiiSNakagakiHMizunoK. Five-year incidence of periodontal disease is related to body mass index. J Dent Res. (2011) 90:199–202. doi: 10.1177/0022034510382548. PMID:

  • 62

    GormanAKayeEKApovianCFungTTNunnM. Overweight and obesity predict time to periodontal disease progression in men. J Clin Periodontology. (2012) 39:107–14. doi: 10.1111/j.1600-051X.2011.01824.x. PMID:

  • 63

    StroberWFussIMannonP. The fundamental basis of inflammatory bowel disease. J Clin Invest. (2007) 117:514–21. doi: 10.1172/JCI30587. PMID:

  • 64

    LauritanoDBoccalariEDi StasioDDella VellaFCarinciF. Prevalence of oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: a systematic review. Diagnostics. (2019) 9:77. doi: 10.3390/diagnostics9030077. PMID:

  • 65

    BaimaGMuwallaMTestaGMazzaFBebarsA. Periodontitis prevalence and severity in inflammatory bowel disease: A case–control study. J Periodontology. (2023) 94:313–22. doi: 10.1002/JPER.22-0322. PMID:

  • 66

    GreuterTBertoldoFRechnerRStraumannABiedermannL. Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation, and anti‐TNF treatment. J Pediatr Gastroenterol Nutr. (2017) 65:200–6. doi: 10.1097/mpg.0000000000001455. PMID:

  • 67

    KoutsochristouVZellosADimakouKPanayotouISiahanidouS. Dental caries and periodontal disease in children and adolescents with inflammatory bowel disease: a case–control study. Inflammatory Bowel Dis. (2015) 21:1839–46. doi: 10.1097/MIB.0000000000000452. PMID:

  • 68

    VelosoFTCarvalhoJMagroF. Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol. (1996) 23:29–34. doi: 10.1097/00004836-199607000-00009. PMID:

  • 69

    LankaraniKBSivandzadehGRHassanpourS. Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterology: WJG. (2013) 19:8571. doi: 10.3748/wjg.v19.i46.8571. PMID:

  • 70

    StorwickGSPrihodaMBFultonRJWoodWS. Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Dermatol. (1994) 31:336–41. doi: 10.1016/S0190-9622(94)70167-9. PMID:

  • 71

    HartySFlemingPRowlandMCrushellEMcDermottMDrummBet al. A prospective study of the oral manifestations of Crohn’s disease. Clin Gastroenterol Hepatol. (2005) 3:886–91. doi: 10.1016/S1542-3565(05)00424-6. PMID:

  • 72

    KatzJShenkmanAStavropoulosFMelzerE. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease. Oral Dis. (2003) 9:34–40. doi: 10.1034/j.1601-0825.2003.00879.x. PMID:

  • 73

    PittockSDrummBFlemingPMcDermottMImrieCFlintSet al. The oral cavity in Crohn’s disease. J Pediatr. (2001) 138:767–71. doi: 10.1067/mpd.2001.113008. PMID:

  • 74

    Muhvić-UrekMTomac-StojmenovićMMijandrušić-SinčićB. Oral pathology in inflammatory bowel disease. World J Gastroenterol. (2016) 22:5655. doi: 10.3748/wjg.v22.i25.5655. PMID:

  • 75

    OjhaJCohenDMIslamNMStewartCMKatzJBhattacharyyaI. Gingival involvement in Crohn disease. J Am Dent Assoc. (2007) 138:1574–81. doi: 10.14219/jada.archive.2007.0106. PMID:

  • 76

    EckelALeeDDeutschGMaxinAOdaD. Oral manifestations as the first presenting sign of Crohn’s disease in a pediatric patient. J Clin Exp Dent. (2017) 9:e934. doi: 10.4317/jced.53914. PMID:

  • 77

    BritoFBarrosFCZaltmanCCarvalhoATPCarneiroAJV. Prevalence of periodontitis and DMFT index in patients with Crohn’s disease and ulcerative colitis. J Clin Periodontology. (2008) 35:555–60. doi: 10.1111/j.1600-051X.2008.01231.x. PMID:

  • 78

    VavrickaSRManserCNHedigerSVoegelinMScharlM. Periodontitis and gingivitis in inflammatory bowel disease: a case–control study. Inflammatory Bowel Dis. (2013) 19:2768–77. doi: 10.1097/01.MIB.0000438356.84263.3b. PMID:

  • 79

    KatsanosKHTorresJRodaGBrygoADelaporteEColombelJF. Non‐malignant oral manifestations in inflammatory bowel diseases. Alimentary Pharmacol Ther. (2015) 42:40–60. doi: 10.1111/apt.13217. PMID:

  • 80

    PapageorgiouSNHagnerMNogueiraAVBFrankeAJaegerA. Inflammatory bowel disease and oral health: systematic review and a meta‐analysis. J Clin Periodontology. (2017) 44:382–93. doi: 10.1111/jcpe.12698. PMID:

  • 81

    HabashnehRAKhaderYSAlhumouzMKJadallahKAjlouniY. The association between inflammatory bowel disease and periodontitis among Jordanians: a case–control study. J Periodontal Res. (2012) 47:293–8. doi: 10.1111/j.1600-0765.2011.01431.x. PMID:

  • 82

    ZhangYQiaoDChenRZhuFGongJ. The association between periodontitis and inflammatory bowel disease: a systematic review and meta‐analysis. BioMed Research International. (2021) 2021(1):6692420. doi: 10.1155/2021/6692420

  • 83

    LiuLJLiJFChenGWYangCWeiJLiLet al. Research progress on the correlation between the gut-liver axis and liver cirrhosis. Chin J Integrated Traditional Western Med Digestion. (2021) 29:222–6.

  • 84

    FurutaMEkuniDYamamotoTIrieKKoyamaR. Relationship between periodontitis and hepatic abnormalities in young adults. Acta Odontol Scand. (2010) 68:27–33. doi: 10.3109/00016350903291913. PMID:

  • 85

    GrønkjærLLHolmstrupPSchouSKongstadJJepsenP. Periodontitis in patients with cirrhosis: a cross-sectional study. BMC Oral Health. (2018) 18:22. doi: 10.1186/s12903-018-0487-5. PMID:

  • 86

    TamakiNTakakiATomofujiTEndoYKasuyamaK. Stage of hepatocellular carcinoma is associated with periodontitis. J Clin Periodontology. (2011) 38:1015–20. doi: 10.1111/j.1600-051X.2011.01777.x. PMID:

  • 87

    YounossiZMKoenigABAbdelatifDFazelYHenryL. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. (2016) 64:73–84. doi: 10.1002/hep.28431. PMID:

  • 88

    YonedaMNakaSNakanoKWadaKEndoH. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. (2012) 12:16. doi: 10.1186/1471-230X-12-16. PMID:

  • 89

    KamataYKessokuTShimizuTSatoSKobayashiT. Periodontal treatment and usual care for nonalcoholic fatty liver disease: a multicenter, randomized controlled trial. Clin Trans Gastroenterol. (2022) 13:e00520. doi: 10.14309/ctg.0000000000000520. PMID:

  • 90

    MarroneALasserreJBercyPBrecxMCMarroneA. Prevalence and risk factors for peri‐implant disease in Belgian adults. Clin Oral Implants Res. (2013) 24:934–40. doi: 10.1111/j.1600-0501.2012.02476.x. PMID:

  • 91

    Ladegaard GrønkjærLHolmstrupPSchouSJepsenPVilstrupH. Severe periodontitis and higher cirrhosis mortality. United Eur Gastroenterol J. (2018) 6:73–80. doi: 10.1177/2050640617715846. PMID:

  • 92

    CostaFOPereira LagesEJBastos LagesEMMiranda CotaLO. Periodontitis in individuals with liver cirrhosis: a case-control study. J Clin Periodontology. (2019) 46:991–8. doi: 10.1111/jcpe.13172. PMID:

  • 93

    MachteiEEFalahMOettinger-BarakOBaruchYHorwitzJ. Periodontal status in post-liver transplantation patients: 10 years of follow-up. Quintessence Int. (2012) 43:879–85.

  • 94

    GaldinoTMOliveiraCSMoreiraANLimeiraFIRMagalhãesCS. Periodontal outcomes in liver transplantation individuals: a systematic review and meta-analysis. J Gastrointestinal Liver Diseases: JGLD. (2021) 30:122–31. doi: 10.15403/jgld-3142. PMID:

  • 95

    WHO International Agency for Research on Cancer. GLOBO-CAN 2012:Estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer.

  • 96

    PushalkarSJiXLiYEstiloCYegnanarayanaR. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol. (2012) 12:144. doi: 10.1186/1471-2180-12-144. PMID:

  • 97

    JemalASiegelRWardEHaoYXuJMurrayTet al. Cancer statistics, 2008. CA Cancer J Clin. (2008) 58:71–96. doi: 10.3322/ca.2007.0010. PMID:

  • 98

    MeiselPHoltfreterBBiffarRSuemnigWKocherT. Association of periodontitis with the risk of oral leukoplakia. Oral Oncol. (2012) 48:859–63. doi: 10.1016/j.oraloncology.2012.02.0220

  • 99

    ZhaoHChuMHuangZYangXRanS. Variations in oral microbiota associated with oral cancer. Sci Rep. (2017) 7:11773. doi: 10.1038/s41598-017-11779-9. PMID:

  • 100

    BrayFLaversanneMSungHFerlayJSiegelRL. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J For Clin. (2024) 74:229–63. doi: 10.3322/caac.21834. PMID:

  • 101

    MichaudDSLiuYMeyerMGiovannucciEJoshipuraK. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol. (2008) 9:550–8. doi: 10.1016/S1470-2045(08)70106-2. PMID:

  • 102

    ChenXYuanZLuMZhangYJinL. Poor oral health is associated with an increased risk of esophageal squamous cell carcinoma‐a population‐based case‐control study in China. Int J Cancer. (2017) 140:626–35. doi: 10.1002/ijc.30484. PMID:

  • 103

    LeeYLHuHYYangNPChouPChuD. Dental prophylaxis decreases the risk of esophageal cancer in males; a nationwide population-based study in Taiwan. PloS One. (2014) 9:e109444. doi: 10.1371/journal.pone.0109444. PMID:

  • 104

    SiegelRLMillerKDJemalA. Cancer statistics, 2015. CA: A Cancer J For Clin. (2015) 65(1):5–29. doi: 10.3322/caac.21254. PMID:

  • 105

    SunJZhouMSalazarCRHaysRBediS. Chronic periodontal disease, periodontal pathogen colonization, and increased risk of precancerous gastric lesions. J Periodontology. (2017) 88:1124–34. doi: 10.1902/jop.2017.160829. PMID:

  • 106

    MeurmanJH. Oral microbiota and cancer. J Oral Microbiol. (2010) 2:5195. doi: 10.3402/jom.v2i0.5195. PMID:

  • 107

    CastellarinMWarrenRLFreemanJDDreoliniLKrzywinskiM. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. (2012) 22:299–306. doi: 10.1101/gr.126516.111. PMID:

  • 108

    Momen-HeraviFBabicATworogerSSZhangLWuK. Periodontal disease, tooth loss and colorectal cancer risk: Results from the Nurses’ Health Study. Int J Cancer. (2017) 140:646–52. doi: 10.1002/ijc.30486. PMID:

  • 109

    YangWSJiangHYLiuCWeiJZhouYGongP. Multi-omics technologies and their clinical applications in hepatocellular carcinoma: current advances and future opportunities. Chin Med Sci J. (2021) 36:173–86. doi: 10.24920/003984. PMID:

  • 110

    YangBPetrickJLAbnetCCGraubardBIMurphyG. Tooth loss and liver cancer incidence in a Finnish cohort. Cancer Causes Control. (2017) 28:899–904. doi: 10.1007/s10552-017-0906-y. PMID:

  • 111

    BrayFFerlayJSoerjomataramLSiegelRLTorreLA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492. PMID:

  • 112

    MaisonneuvePAmarSLowenfelsAB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann Oncol. (2017) 28:985–95. doi: 10.1093/annonc/mdx019. PMID:

  • 113

    ChangISTsaiCRChenLTShanYS. Investigating the association between periodontal disease and risk of pancreatic cancer. Pancreas. (2016) 45:134–41. doi: 10.1097/mpa.0000000000000419. PMID:

  • 114

    HuangJRoosaarAAxellTYeW. A prospective cohort study on poor oral hygiene and pancreatic cancer risk. Int Cancer. (2016) 138:340–7. doi: 10.1002/jc.29710. PMID:

  • 115

    MaoYSYangDHeJKrasnaMJ. Epidemiology of lung cancer. Surg Oncol Clin North Am. (2016) 25:439–45. doi: 10.1016/j.soc.2016.02.001. PMID:

  • 116

    ZengXTXiaLYZhangYGLiSLengWD. Periodontal disease and incident lung cancer risk: a meta‐analysis of cohort studies. J Periodontology. (2016) 87:1158–64. doi: 10.1902/jop.2016.150597. PMID:

  • 117

    MaiXDLaMonteMJHoveyKMFreudenheimJLAndrewsCA. Periodontal disease severity and cancer risk in postmenopausal women: the buffalo OsteoPerio study. Cancer Causes Control. (2016) 27:217–28. doi: 10.1007/s10552-015-0699-9. PMID:

  • 118

    MichaudDSLuJPeacock-VilladaAYBarberJRJoshuCE. Periodontal disease assessed using clinical dental measurements and cancer risk in the ARIC study. JNCI: J Natl Cancer Institute. (2018) 110:843–54. doi: 10.1093/jnci/djx278. PMID:

  • 119

    HwangIMSunLMLinCLLeeCFKaoCH. Periodontal disease with treatment reduces subsequent cancer risks. QJM: Int J Med. (2014) 107:805–12. doi: 10.1093/qjmed/hcu078. PMID:

  • 120

    BalajamNZMousavianAHSheidaeiAGohariKTavangarSM. The 15-year national trends of endocrine cancers incidence among Iranian men and women; 2005–2020. Sci Rep. (2023) 13:7632. doi: 10.1038/s41598-023-34155-2. PMID:

  • 121

    KimEHNamSParkCHKimYLeeM. Periodontal disease and cancer risk: A nationwide population-based cohort study. Front Oncol. (2022) 12:901098. doi: 10.3389/fonc.2022.901098. PMID:

  • 122

    DesailloudRHoberD. Viruses and thyroiditis: an update. Virol J. (2009) 6:5. doi: 10.1186/1743-422X-6-5. PMID:

  • 123

    FreudenheimJLGencoRJLaMonteMJMillenAEHoveyKM. Periodontal disease and breast cancer: prospective cohort study of postmenopausal women. Cancer Epidemiology Biomarkers Prev. (2016) 25:43–50. doi: 10.1158/1055-9965.EPI-15-0750. PMID:

  • 124

    SfreddoCSMaierJDe DavidSCSusinCMoreiraCHC. Periodontitis and breast cancer: A case-control study. Community Dent Oral Epidemiol. (2017) 45:545–51. doi: 10.1111/cdoe.12318. PMID:

  • 125

    BrownPPrattAGHyrichKL. Therapeutic advances in rheumatoid arthritis. BMJ. (2024) 384(1):62–70. doi: 10.1111/j.1479-8077.2004.00062.x. PMID:

  • 126

    Lopez OlivaIMalcolmJCulshawS. Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases. Periodontology 2000. (2024). doi: 10.1111/prd.12530. PMID:

  • 127

    ErikssonKFeiGLundmarkABenchimolDLeeL. Periodontal health and oral microbiota in patients with rheumatoid arthritis. J Clin Med. (2019) 8:630. doi: 10.3390/jcm8050630. PMID:

  • 128

    QiaoYWangZLiYHanYZhouY. Rheumatoid arthritis risk in periodontitis patients: a systematic review and meta-analysis. Joint Bone Spine. (2020) 87:556–64. doi: 10.1016/j.jbspin.2020.04.024. PMID:

  • 129

    SilvaDSDe VriesCRoviscoJSerraSKaminskaM. The impact of periodontitis and periodontal treatment on rheumatoid arthritis outcomes: an exploratory clinical trial. Rheumatology. (2025) 64:1679–88. doi: 10.1093/rheumatology/keae358. PMID:

  • 130

    KobayashiTItoSYasudaKKurodaTYamamotoK. The combined genotypes of stimulatory and inhibitory Fcγ receptors associated with systemic lupus erythematosus and periodontitis in Japanese adults. J Periodontology. (2007) 78:467–74. doi: 10.1902/jop.2007.060194. PMID:

  • 131

    FabbriCFullerRBonfáEGuedesLKND'AllevaPSR. Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy. Clin Rheumatol. (2014) 33:505–9. doi: 10.1007/s10067-013-2473-2. PMID:

  • 132

    CorrêaJDCalderaroDCFerreiraGASouza MendoncaSMFernandesGR. Subgingival microbiota dysbiosis in systemic lupus erythematosus: association with periodontal status. Microbiome. (2017) 5:34. doi: 10.1186/s40168-017-0252-z. PMID:

  • 133

    WangYYLinXP. Detection and significance of IL-6 and TNF-α in patients with Graves’ disease and concurrent periodontitis. Shanghai J Stomatology. (2018) 27:43–7. doi: 10.19439/j.sjos.2018.01.010

  • 134

    ChenXTTanJYLeiLHChenLL. Cytokine levels in plasma and gingival crevicular fluid in chronic periodontitis. Am J Dentistry. (2015) 28:9–12. doi: 10.1034/j.1600-051x.2000.027005366.x. PMID:

  • 135

    TakasuNYamadaTSatoANakagawaMKomiyaINagasawaYet al. Graves’ disease following hypothyroidism due to Hashimoto’s disease: studies of eight cases. Clin Endocrinol. (1990) 33:687–98. doi: 10.1111/j.1365-2265.1990.tb03906.x. PMID:

  • 136

    GaurSAgnihotriR. Alzheimer’s disease and chronic periodontitis: is there an association? Geriatrics Gerontology Int. (2015) 15:391–404. doi: 10.1111/ggi.12425. PMID:

  • 137

    Roubaud BaudronCLetenneurLLanglaisABuissonnièreAMégraudF. Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agées QUID Study. J Am Geriatrics Soc. (2013) 61:74–8. doi: 10.1111/jgs.12065. PMID:

  • 138

    SteinPSSteffenMJSmithCJichaGEbersoleJL. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimer’s Dementia. (2012) 8:196–203. doi: 10.1016/j.jalz.2011.04.006. PMID:

  • 139

    ChoiSKimKChangJKimSMKimSJChoHJet al. Association of chronic periodontitis on Alzheimer’s disease or vascular dementia. J Am Geriatrics Soc. (2019) 67:1234–9. doi: 10.1111/jgs.15828. PMID:

  • 140

    FleuryVZekeridouALazarevicVGaïaNGiannopoulouCGentonLet al. Oral dysbiosis and inflammation in Parkinson’s disease. J Parkinson’s Dis. (2021) 11:619–31. doi: 10.3233/JPD-202459. PMID:

  • 141

    ChenCKWuYTChangYC. Periodontal inflammatory disease is associated with the risk of Parkinson’s diseasea population-based retrospective matched-cohort study. Peerl. (2017) 5:e3647. doi: 10.7717/peerj.3647. PMID:

  • 142

    VerhoeffMCEikenboomDKoutrisMVriesRBerendseHWDijkKD. Parkinson’s disease and oral health: A systematic review. Arch Oral Biol. (2023) 151:105712. doi: 10.1016/j.archoralbio.2023.105712. PMID:

  • 143

    WooHGChangYLeeJSSongTJ. Association of tooth loss with new‐onset Parkinson’s disease: A nationwide population‐based cohort study. Parkinson’s Dis. (2020) 2020:4760512. doi: 10.1155/2020/4760512. PMID:

  • 144

    HammenC. Risk factors for depression: an autobiographical review. Annu Rev Clin Psychol. (2018) 14:1–28. doi: 10.1146/annurev-clinpsy-050817084811. PMID:

  • 145

    RosaniaAELowKGMcCormickCMRosaniaDA. Stress, depression, cortisol, and periodontal disease. J Periodontology. (2009) 80:260–6. doi: 10.1902/jop.2009.080334. PMID:

  • 146

    WarrenKRPostolacheTTGroerMEPinjariOKellyDL. Role of chronic stress and depression in periodontal diseases. Periodontology 2000. (2014) 64:127–38. doi: 10.1111/prd.12036. PMID:

  • 147

    TangYHCaoFY. Investigation and analysis of depression occurrence in patients with chronic periodontitis. Shanghai Kou Qiang Yi Xue. (2011) 20:74–7.

  • 148

    HsuCCHsuYCChenHJLinCCChangKH. Association of periodontitis and subsequent depression: a nationwide population-based study. Medicine. (2015) 94:e2347. doi: 10.1097/MD.0000000000002347. PMID:

  • 149

    SinghMWambuaSLeeSIOkothKWangZ. Autoimmune diseases and adverse pregnancy outcomes: an umbrella review. BMC Med. (2024) 22:94. doi: 10.1186/s12916-024-03309-y. PMID:

  • 150

    VamosCAThompsonELAvendanoMDaleyEMQuinonezRB. Oral health promotion interventions during pregnancy: a systematic review. Community Dentistry Oral Epidemiol. (2015) 43:385–96. doi: 10.1111/cdoe.12167. PMID:

  • 151

    MohrSAmylidi-MohrSKStadelmannPSculeanAPerssonR. Systemic inflammation in pregnant women with periodontitis and preterm prelabor rupture of membranes: a prospective case-control study. Front Immunol. (2019) 10:2624. doi: 10.3389/fimmu.2019.02624. PMID:

  • 152

    BondJCWiseLAFoxMPGarciaRIMurrayEJ. Preconception periodontitis and risk of spontaneous abortion in a prospective cohort study. Am J Epidemiol. (2023) 192:1509–21. doi: 10.1093/aje/kwad142. PMID:

  • 153

    MahapatraANayakRSatpathyAPatiBKMohantyR. Maternal periodontal status, oral inflammatory load, and systemic inflammation are associated with low infant birth weight. J Periodontology. (2021) 92:1107–16. doi: 10.1002/JPER.20-0266. PMID:

  • 154

    BoggessKA. Choosing the left fork: Steven Offenbacher and understanding maternal periodontal disease and adverse pregnancy outcomes. J Periodontology. (2020) 91:S40–4. doi: 10.1002/JPER.20-0090. PMID:

  • 155

    TavarnaTPhillipsPLWuXReyesL. Fetal growth restriction is a host specific response to infection with an impaired spiral artery remodeling-inducing strain of Porphyromonas gingivalis. Sci Rep. (2020) 10:14606. doi: 10.1038/s41598-020-71762-9. PMID:

  • 156

    LiuFSuiWZhouZFet al. Development of gestational diabetes mellitus in women with periodontitis in early pregnancy: A population‐based clinical study. J Clin Periodontology. (2022) 49:164–76. doi: 10.1111/jcpe.13578. PMID:

  • 157

    WahlPDucasaGMFornoniA. Systemic and renal lipids in kidney disease development and progression. Am J Physiol Renal Physiol. (2016) 310:F433–45. doi: 10.1152/ajprenal.00375.2015. PMID:

  • 158

    KshirsagarAVMossKLElterJRBeckJDOffenbacherS. Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis. (2005) 45:650–7. doi: 10.1053/j.ajkd.2004.12.009. PMID:

  • 159

    ChangJFYehJCChiuYLLiouJCHsiungJR. Periodontal pocket depth, hyperglycemia, and progression of chronic kidney disease: a population-based longitudinal study. Am J Med. (2017) 130:61–9. doi: 10.1016/j.amjmed.2016.08.024. PMID:

  • 160

    GrubbsVVittinghoffETaylorGKritz-SilversteinDPoweN. The association of periodontal disease with kidney function declinea longitudinal retrospective analysis of the MrOS dental study. Nephrol Dial Transplant. (2016) 31:466–72. doi: 10.1093/ndt/gfv312. PMID:

  • 161

    LipskyBAByrenIHoeyCT. Treatment of bacterial prostatitis. Clin Infect Dis. (2010) 50:1641–52. doi: 10.1086/652861. PMID:

  • 162

    WuLLiBHWangYYWangCYZiH. Periodontal disease and risk of benign prostate hyperplasia: a cross-sectional study. Mil Med Res. (2019) 6:34. doi: 10.1186/s40779-019-0223-8. PMID:

  • 163

    ByunSHMinCYBangWYangBEHongSJ. A cross-sectional study for association between periodontitis and benign prostatic hyperplasia using the Korean genome and epidemiology study data. Coatings. (2022) 12:265. doi: 10.3390/coatings12020265. PMID:

  • 164

    Nguyen NielsenMBorreM. Diagnostic and therapeutic strategies for prostate cancer. Semin NucdI Med. (2016) 46:484–90. doi: 10.1053/j.semnuclmed.2016.07.002. PMID:

  • 165

    GüvenDCDizdarÖAkmanACBerkerEYekeduzE. Evaluation of cancer risk in patients with periodontal diseases. Turk J Med Sci. (2019) 49:826–31. doi: 10.3906/sag-1812-8. PMID:

  • 166

    LeeJHKweonHHIChoiJKKimYTChoiSH. Association between periodontal disease and prostate cancer: results of a 12-year longitudinal cohort study in South Korea. J Cancer. (2017) 8:2959. doi: 10.7150/jca.20532. PMID:

  • 167

    MeurmanJHKällménHAnderssonLCYucel-LindbergTSoderB. Prevalence of cancer in relation to signs of periodontal inflammation. PloS One. (2022) 17:e0276375. doi: 10.1371/journal.pone.0276375. PMID:

  • 168

    CenterJEismanJ. The epidemiology and pathogenesis of osteoporosis. Baillieres Clin Endocrinol Metab. (1997) 11(4):719–40. doi: 10.1016/S0950-351X(97)80489-2

  • 169

    TakI-HShinM-HKweonS-SNamHSCauleyJA. The association between periodontal disease, tooth loss and bone mineral density in a Korean population. J Clin Periodontology. (2014) 41:1139–44. doi: 10.1111/jcpe.12309. PMID:

  • 170

    Al HabashnehRAlchalabiHKhaderYSHazza'aAMOdatZ. Association between periodontal disease and osteoporosis in postmenopausal women in Jordan. J Periodontology. (2010) 81:1613–21. doi: 10.1902/jop.2010.100190. PMID:

  • 171

    Gil-MontoyaJAGarrido-MartínezMBarrios-RodríguezRRamos-GarciaPLenouvelD. Association between low bone mineral density and periodontitis in generally healthy perimenopausal women. J Periodontology. (2021) 92:95–103. doi: 10.1002/JPER.20-0029. PMID:

  • 172

    HuangYFChangCTLiuSPMuoCHTsaiCHHongHHet al. The impact of oral hygiene maintenance on the association between periodontitis and osteoporosis: a nationwide population-based cross sectional study. Medicine. (2016) 95:e2348. doi: 10.1097/MD.0000000000002348. PMID:

  • 173

    ChoiJ-KKimY-TKweonH-IParkECChoiSH. Effect of periodontitis on the development of osteoporosis: results from a nationwide population-based cohort study (2003-2013). BMC Womens Health. (2017) 17:77. doi: 10.1186/s12905-017-0440-9. PMID:

  • 174

    SatoYOkamotoKKagamiAYamamotoYIgarashiTKizakiH. Streptococcus mutans strains harboring collagen-binding adhesin. J Dent Res. (2004) 83:534–9. doi: 10.1177/154405910408300705. PMID:

  • 175

    NakaSNomuraROoshimaTTaniguchiKInagakiS. Potential involvement of collagen-binding proteins of S treptococcus mutans in infective endocarditis. Oral Dis. (2013) 19:387–93. doi: 10.1111/odi.12016. PMID:

  • 176

    NomuraRNakaSNemotoHOtsuguMNakamuraS. Potential high virulence for infective endocarditis in Streptococcus mutans strains with collagen-binding proteins but lacking PA expression. Arch Oral Biol. (2013) 58:1627–34. doi: 10.1016/j.archoralbio.2013.06.008. PMID:

  • 177

    MisakiTNakaSKurodaKNomuraRShiookaT. Distribution of Streptococcus mutans strains with collagen-binding proteins in the oral cavity of IgA nephropathy patients. Clin Exp Nephrol. (2015) 19:844–50. doi: 10.1007/s10157-014-1072-0. PMID:

  • 178

    MisakiTNakaSHatakeyamaRFukunagaANomuraR. Presence of Streptococcus mutans strains harbouring the cnm gene correlates with dental caries status and IgA nephropathy conditions. Sci Rep. (2016) 6:36455. doi: 10.1038/srep36455. PMID:

  • 179

    MisakiTNakaSWatoKHatakeyamaRNagasawaY. Campylobacter rectus in the oral cavity correlates with proteinuria in immunoglobulin A nephropathy patients. Nephron. (2018) 139:143–9. doi: 10.1159/000487103. PMID:

  • 180

    ItoSMisakiTNakaSWatoKNagasawaY. Specific strains of Streptococcus mutans, a pathogen of dental caries, in the tonsils, are associated with IgA nephropathy. Sci Rep. (2019) 9:20130. doi: 10.1038/s41598-019-56679-2. PMID:

  • 181

    NakaSWatoKMisakiTItoSNagasawaY. Intravenous administration of Streptococcus mutans induces IgA nephropathy-like lesions. Clin Exp Nephrol. (2020) 24:1122–31. doi: 10.1007/s10157-020-01961-1. PMID:

  • 182

    NakaSWatoKMisakiTItoSMatsuokaD. Streptococcus mutans induces IgA nephropathy-like glomerulonephritis in rats with severe dental caries. Sci Rep. (2021) 11:5784. doi: 10.1038/s41598-021-85196-4. PMID:

  • 183

    SunJTangQYuSXieMZhengW. F. nucleatum facilitates oral squamous cell carcinoma progression via GLUT1-driven lactate production. eBioMedicine. (2023) 88:104444. doi: 10.1016/j.ebiom.2023.104444. PMID:

  • 184

    YangCYYehYMYuHYChinCYHsuCW. Oral microbiota community dynamics associated with oral squamous cell carcinoma staging. Front Microbiol. (2018) 9:862. doi: 10.3389/fmicb.2018.00862. PMID:

  • 185

    Mitchell LewisDEngebretsonSPChenJLamsterIBPapapanouPN. Periodontal infections and pre-term birth: early findings from a cohort of young minority women in New York. Eur J Oral Sci. (2001) 109:34–9. doi: 10.1034/j.1600-0722.2001.00966.x. PMID:

  • 186

    SánchezARKuppLISheridanPJSanchezDR. Maternal chronic infection as a risk factor in preterm low birth weight infants: the link with periodontal infection. J Int Acad Periodontology. (2004) 6:89–94.

  • 187

    OffenbacherSLinDStraussRMcKaigRIrvingJ. Effects of periodontal therapy during pregnancy on periodontal status, biologic parameters, and pregnancy outcomes: a pilot study. J Periodontology. (2006) 77:2011–24. doi: 10.1902/jop.2006.060047. PMID:

  • 188

    SilvaNLeónRChaparroAOvalleAGajardoM. Detection of Porphyromonas gingivalis in the amniotic fluid in pregnant women with a diagnosis of threatened premature labor. J Periodontology. (2007) 78:1249–55. doi: 10.1902/jop.2007.060368. PMID:

  • 189

    DesvarieuxMDemmerRTJacobsDRRundekTBoden-AlbalaB. Periodontal bacteria and hypertension: the oral infections and vascular disease epidemiology study (INVEST). J Hypertens. (2010) 28:1413–21. doi: 10.1097/HJH.0b013e328338cd36. PMID:

  • 190

    Czesnikiewicz GuzikMNosalskiRMikolajczykTPVidlerFDohnalT. Th1-type immune responses to Porphyromonas gingivalis antigens exacerbate angiotensin II-dependent hypertension and vascular dysfunction. Br J Pharmacol. (2019) 176:1922–31. doi: 10.1111/bph.14536. PMID:

  • 191

    AbranchesJZengLKajfaszJKPalmerSRChakrabortyBWenZTet al. Biology of oral streptococci. Microbiol Spectr. (2018) 6:gpp3-0042-2018. doi: 10.1128/microbiolspec.gpp3-0042-2018. PMID:

  • 192

    PietropaoliDDel PintoRFerriCOrtuEMonacoA. Definition of hypertension-associated oral pathogens in NHANES. J Periodontology. (2019) 90:866–76. doi: 10.1002/JPER.19-0046. PMID:

  • 193

    AkhiRLavrinienkoAHakulaMOrtuEMonacoA. Oral microbiota linking humoral response, periodontitis and atherosclerosis. J Clin Periodontology. (2025) 52:1550–9. doi: 10.1111/jcpe.70001. PMID:

  • 194

    KawasakiMIkedaYIkedaETakahashiMTanaka. Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer. Cancer. (2021) 127:512–9. doi: 10.1002/cncr.33316. PMID:

  • 195

    IsmailFBIsmailGDumitriuASBastonCBerbecarV. Identification of subgingival periodontal pathogens and association with the severity of periodontitis in patients with chronic kidney diseases: a cross-sectional study. BioMed Res Int. (2015) 2015:370314. doi: 10.1155/2015/370314. PMID:

  • 196

    CastilloAMesaFLiébanaJGarcia-MartinezORuizS. Periodontal and oral microbiological status of an adult population undergoing haemodialysis: a cross-sectional study. Oral Dis. (2007) 13:198–205. doi: 10.1111/j.1601-0825.2006.01267.x. PMID:

  • 197

    Hernández CabanyeroCVonaeschP. Ectopic colonization by oral bacteria as an emerging theme in health and disease. FEMS Microbiol Rev. (2024) 48:fuae012. doi: 10.1093/femsre/fuae012. PMID:

  • 198

    HorlianaACRTChambroneLFozAMArteseHPCRabeloMS. Dissemination of periodontal pathogens in the bloodstream after periodontal procedures: a systematic review. PloS One. (2014) 9:e98271. doi: 10.1371/journal.pone.0098271. PMID:

  • 199

    XueYXiaoHGuoSXuBLiaoY. Indoleamine 2, 3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages. Cell Death Dis. (2018) 9:355. doi: 10.1038/s41419-018-0389-0. PMID:

  • 200

    KamadaNChenGYInoharaNNunezG. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. (2013) 14:685–90. doi: 10.1038/ni.2608. PMID:

  • 201

    RolhionNChassaingB. When pathogenic bacteria meet the intestinal microbiota. Philos Trans R Soc B Biol Sci. (2016) 371:20150504. doi: 10.1098/rstb.2015.0504. PMID:

  • 202

    SorbaraMTPamerEG. Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. Mucosal Immunol. (2019) 12:1–9. doi: 10.1038/s41385-018-0053-0. PMID:

  • 203

    SalazarCRSunJLiYFrancoisFCorbyP. Association between selected oral pathogens and gastric precancerous lesions. PloS One. (2013) 8:e51604. doi: 10.1371/journal.pone.0051604. PMID:

  • 204

    TanQMaXYangBLiuYXieY. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes. (2022) 14:2073785. doi: 10.1080/19490976.2022.2073785. PMID:

  • 205

    FlemerBLynchDBBrownJMRJefferyIBRyanFJClaessonMJ. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. (2017) 66:633–43. doi: 10.1136/gutjnl-2017-314219. PMID:

  • 206

    BaxterNTRuffinMTRogersMAMSchlossPD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med. (2016) 8:37. doi: 10.1186/s13073-016-0290-3. PMID:

  • 207

    ZellerGTapJVoigtAYSunagawaShinichiKultimaJens Roat. Potential of fecal microbiota for early‐stage detection of colorectal cancer. Mol Syst Biol. (2014) 10:766. doi: 10.15252/msb.20145645. PMID:

  • 208

    WarrenRLFreemanDJPleasanceSWatsonPMooreRA. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome. (2013) 1:16. doi: 10.1186/2049-2618-1-16. PMID:

  • 209

    KosticADGeversDPedamalluCSMichaudMDukeF. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. (2012) 22:292–8. doi: 10.1101/gr.126573.111. PMID:

  • 210

    KosticADChunERobertsonLGlickmanJNGalliniCA. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. (2013) 14:207–15. doi: 10.1016/j.chom.2013.07.007. PMID:

  • 211

    NakatsuGLiXZhouHShengJWongSH. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. (2015) 6:8727. doi: 10.1038/ncomms9727. PMID:

  • 212

    LiangQChiuJChenYHuangYHigashimoriA. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. (2017) 23:2061–70. doi: 10.1158/1078-0432.CCR-16-1599. PMID:

  • 213

    KitamotoSNagao-KitamotoHJiaoYGillillandMGHayashiA. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell. (2020) 182:447–62:e14. doi: 10.1016/j.cell.2020.05.048. PMID:

  • 214

    ArimatsuKYamadaHMiyazawaHMinagawaTNakajimaM. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. (2014) 4:4828. doi: 10.1038/srep04828. PMID:

  • 215

    LiuHRedlineRWHanYW. Fusobacterium nucleatum induces fetal death in mice via stimulation of TLR4-mediated placental inflammatory response. J Immunol. (2007) 179:2501–8. doi: 10.4049/jimmunol.179.4.2501. PMID:

  • 216

    AbedJMaaloufNMansonALEarlAMParhiL. Colon cancer-associated Fusobacterium nucleatum may originate from the oral cavity and reach colon tumors via the circulatory system. Front Cell Infect Microbiol. (2020) 10:400. doi: 10.3389/fcimb.2020.00400. PMID:

  • 217

    CarmeliYTroilletNEliopoulosGMSamoreMH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. (1999) 43:1379–82. doi: 10.1128/aac.43.6.1379. PMID:

  • 218

    ScannapiecoFAShayK. Oral health disparities in older adults: oral bacteria, inflammation, and aspiration pneumonia. Dental Clinics. (2014) 58:771–82. doi: 10.1016/j.cden.2014.06.005. PMID:

  • 219

    Gomes-FilhoISCruzSSTrindadeSCPassos-SoaresJSCarvalho-FilhoPC. Periodontitis and respiratory diseases: A systematic review with meta-analysis. Oral Dis. (2020) 26:439–46. doi: 10.1111/odi.13228. PMID:

  • 220

    ZhangQLiCWorthingtonHVLiCWorthingtonHV. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Systematic Rev. (2020) 12(12):CD008367. doi: 10.1002/14651858.CD008367.pub4. PMID:

  • 221

    TakeuchiKMatsumotoKFurutaMFukuyamaSTakeshitaT. Periodontitis is associated with chronic obstructive pulmonary disease. J Dent Res. (2019) 98:534–40. doi: 10.1177/0022034519833630. PMID:

  • 222

    El-SolhAAPietrantoniCBhatAOkadaMZambonJ. Colonization of dental plaques: a reservoir of respiratory pathogens for hospital-acquired pneumonia in institutionalized elders. Chest. (2004) 126:1575–82. doi: 10.1016/S0012-3692(15)31374-X

  • 223

    CaoX. Intestinal inflammation induced by oral bacteria. Science. (2017) 358:308–9. doi: 10.1126/science.aap9298. PMID:

  • 224

    GencoRJVan DykeTE. Reducing the risk of CVD in patients with periodontitis. Nat Rev Cardiol. (2010) 7:479–80. doi: 10.1038/nrcardio.2010.120. PMID:

  • 225

    BrodalaNMerricksEPBellingerDADamrongsriDOffenbacherS. Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arteriosclerosis Thrombosis Vasc Biol. (2005) 25:1446–51. doi: 10.1161/01.ATV.0000167525.69400.9c. PMID:

  • 226

    AagaardKMaJAntonyKMGanuRPetrosinoJVersalovicJ. The placenta harbors a unique microbiome. Sci Transl Med. (2014) 6:237ra65. doi: 10.1126/scitranslmed.3008599. PMID:

  • 227

    HanYWWangX. Mobile microbiome: oral bacteria in extra-oral infections and inflammation. J Dent Res. (2013) 92:485–91. doi: 10.1177/0022034513487559. PMID:

  • 228

    SanzMKornmanKWorking Group 3 of the Joint EFP/AAP Workshop. Periodontitis and adverse pregnancy outcomes: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontology. (2013) 84:S164–9. doi: 10.1111/jcpe.12083. PMID:

  • 229

    Komine-AizawaSAizawaSHayakawaS. Periodontal diseases and adverse pregnancy outcomes. J Obstetrics Gynaecology Res. (2019) 45:5–12. doi: 10.1111/jog.13782. PMID:

  • 230

    KaurMGeisingerMLGeursNCGriffinRVassilopoulosPJ. Effect of intensive oral hygiene regimen during pregnancy on periodontal health, cytokine levels, and pregnancy outcomes: a pilot study. J Periodontology. (2014) 85:1684–92. doi: 10.1902/jop.2014.140248. PMID:

  • 231

    LinDMossKBeckJDHeftiAOffenbacherS. Persistently high levels of periodontal pathogens associated with preterm pregnancy outcome. J Periodontology. (2007) 78:833–41. doi: 10.1902/jop.2007.060201. PMID:

  • 232

    HanYWFardiniYChenCIacampoKGPerainoVA. Term stillbirth caused by oral Fusobacterium nucleatum. Obstetrics Gynecology. (2010) 115:442–5. doi: 10.1097/AOG.0b013e3181cb9955. PMID:

  • 233

    HanYW. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol. (2015) 23:141–7. doi: 10.1016/j.mib.2014.11.013. PMID:

  • 234

    GauthierSTétuAHimayaEMorandMChandadF. The origin of Fusobacterium nucleatum involved in intra-amniotic infection and preterm birth. J Maternal-Fetal Neonatal Med. (2011) 24:1329–32. doi: 10.3109/14767058.2010.550977. PMID:

  • 235

    KatzJCheginiNShiverickKTLamontRJ. Localization of P. gingivalis in preterm delivery placenta. J Dent Res. (2009) 88:575–8. doi: 10.1177/0022034509338032. PMID:

  • 236

    ReyesLPhillipsPWolfeBGolosTGWalkenhorstM. Porphyromonas gingivalis and adverse pregnancy outcome. J Oral Microbiol. (2017) 9:1374153. doi: 10.1080/20002297.2017.1374153. PMID:

  • 237

    CrooksTAMadisonJDWalshDMHerbertWGJeraldoPR. Porphyromonas somerae invasion of endometrial cancer cells. Front Microbiol. (2021) 12:674835. doi: 10.3389/fmicb.2021.674835. PMID:

  • 238

    KunnenAVan PampusMGAarnoudseJGVan der SchansCPAbbasF. The effect of Porphyromonas gingivalis lipopolysaccharide on pregnancy in the rat. Oral Dis. (2014) 20:591–601. doi: 10.1111/odi.12177. PMID:

  • 239

    EscaldaCBotelhoJMendesJJMachadoV. Association of bacterial vaginosis with periodontitis in a cross-sectional American nationwide survey. Sci Rep. (2021) 11:630. doi: 10.1038/s41598-020-79496-4. PMID:

  • 240

    KitamotoSKamadaN. Periodontal connection with intestinal inflammation: Microbiological and immunological mechanisms. Periodontology 2000. (2022) 89:142–53. doi: 10.1111/prd.12424. PMID:

  • 241

    PooleSSinghraoSKKesavaluLCurtisMACreanS. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer’s disease brain tissue. J Alzheimer’s Dis. (2013) 36:665–77. doi: 10.3233/JAD-121918. PMID:

  • 242

    EllenRPGalimanasVB. Spirochetes at the forefront of periodontal infections. Periodontology 2000. (2005) 38:13–32. doi: 10.1111/j.1600-0757.2005.00108.x. PMID:

  • 243

    RoulisEBachmannNLMyersGSAHustonWSummersgillJ. Comparative genomic analysis of human Chlamydia pneumoniae isolates from respiratory, brain and cardiac tissues. Genomics. (2015) 106:373–83. doi: 10.1016/j.ygeno.2015.09.008. PMID:

  • 244

    HammondCJHallockLRHowanskiRJAppeltDMLittleCSBalinBJ. Immunohistological detection of Chlamydia pneumoniae in the Alzheimer’s disease brain. BMC Neurosci. (2010) 11:121. doi: 10.1186/1471-2202-11-121. PMID:

  • 245

    PooleSSinghraoSKChukkapalliSRiveraMVelskoI. Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE-/-mice brains. J Alzheimer’s Dis. (2014) 43:67–80. doi: 10.3233/978-1-61499-706-1-119. PMID:

  • 246

    EstemalikJDemkoCBissadaNFJoshiNBodnerD. Simultaneous detection of oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. J Periodontology. (2017) 88:823–9. doi: 10.1902/jop.2017.160477. PMID:

  • 247

    AlluriLSCPaes Batista da SilvaAVermaSFuPShenDL. Presence ofspecilic periodontal pathogens in prostate gland diagnosed withchronic inflammation and adenocarcinoma. Cureus. (2021) 13:e17742. doi: 10.7759/cureus.17742. PMID:

  • 248

    HajishengallisG. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. (2015) 15:30–44. doi: 10.1038/nri3785. PMID:

  • 249

    GrossiSGGencoRJ. Periodontal disease and diabetes mellitus: a two‐way relationship. Ann Periodontology. (1998) 3:51–61. doi: 10.1902/annals.1998.3.1.51. PMID:

  • 250

    ParaskevasSHuizingaJDLoosBG. A systematic review and meta‐analyses on C‐reactive protein in relation to periodontitis. J Clin Periodontology. (2008) 35:277–90. doi: 10.1111/j.1600-051X.2007.01173.x. PMID:

  • 251

    CutandoALópez-ValverdeAde DiegoRGde VicenteJReiterR. Effect of topical application of melatonin to the gingiva on salivary osteoprotegerin, RANKL and melatonin levels in patients with diabetes and periodontal disease. Odontology. (2014) 102:290–6. doi: 10.1007/s10266-013-0122-5. PMID:

  • 252

    MacielSSFeresMGonçalvesTEDZimmermannGSPereira da SilvaHD. Does obesity influence the subgingival microbiota composition in periodontal health and disease? J Clin Periodontology. (2016) 43:1003–12. doi: 10.1111/jcpe.12634. PMID:

  • 253

    SuvanJD’AiutoFMolesDRPetrieADonosN. Association between overweight/obesity and periodontitis in adults. A systematic review. Obes Rev. (2011) 12:e381–404. doi: 10.1111/jcpe.12634. PMID:

  • 254

    Martinez‐HerreraMSilvestreFJSilvestre‐RangilJBanulsCRochaM. Involvement of insulin resistance in normoglycaemic obese patients with periodontitis: A cross‐sectional study. J Clin Periodontology. (2017) 44:981–8. doi: 10.1111/jcpe.12773. PMID:

  • 255

    GencoRJGrossiSGHoANishimuraFMurayamaY. A proposed model linking inflammation to obesity, diabetes, and periodontal infections. J Periodontology. (2005) 76:2075–84. doi: 10.1902/jop.2005.76.11-S.2075. PMID:

  • 256

    DaiutoFNibaliLParkarMPatelKSuvanJ. Oxidative stress, systemic inflammation, and severe periodontitis. J Dent Res. (2010) 89:1241–6. doi: 10.1177/0022034510375830. PMID:

  • 257

    BullonPMorilloJMRamirez-TortosaMCQuilesJLNewmanHN. Metabolic syndrome and periodontitis: is oxidative stress a common link? J Dent Res. (2009) 88:503–18. doi: 10.1177/0022034509337479. PMID:

  • 258

    NibaliLStephenAHagi-PavliEAllakerRPinoAD. Analysis of gingival crevicular fluid biomarkers in patients with metabolic syndrome. J Dentistry. (2022) 118:104065. doi: 10.1016/j.jdent.2022.104065. PMID:

  • 259

    MustaphaIZDebreySOladubuMUgarteR. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta‐analysis. J Periodontology. (2007) 78:2289–302. doi: 10.1902/jop.2007.070140. PMID:

  • 260

    YuYHChasmanDIBuringJERoseLRidkerPM. Cardiovascular risks associated with incident and prevalent periodontal disease. J Clin Periodontology. (2015) 42:21–8. doi: 10.1111/jcpe.12335. PMID:

  • 261

    SaffiMALFurtadoMVPolanczykCAMontenegroMMRibeiroIWGKampitsC. Relationship between vascular endothelium and periodontal disease in atherosclerotic lesions. World J Cardiol. (2015) 7:26. doi: 10.4330/wjc.v7.i1.26. PMID:

  • 262

    TonettiMSGreenwellHKornmanKS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontology. (2018) 89:S159–72. doi: 10.1111/jcpe.12945. PMID:

  • 263

    OlivierVDunyach-RemyCLavigneJPMoranneO. Micro-inflammation and digestive bacterial translocation in chronic kidney disease. Néphrologie Thérapeutique. (2018) 14:135–41. doi: 10.1016/j.nephro.2017.10.005. PMID:

  • 264

    ChambroneLFozAMGuglielmettiMRPannutiCMArteseHPC. Periodontitis and chronic kidney disease: a systematic review of the association of diseases and the effect of periodontal treatment on estimated glomerular filtration rate. J Clin Periodontology. (2013) 40:443–56. doi: 10.1111/jcpe.12067. PMID:

  • 265

    LertpimonchaiARattanasiriSTamsailomSChampaiboonCIngsathitA. Periodontitis as the risk factor of chronic kidney disease: Mediation analysis. J Clin Periodontology. (2019) 46:631–9. doi: 10.1111/jcpe.13114. PMID:

  • 266

    HowrenMBLamkinDMSulsJ. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Biopsychosocial Sci Med. (2009) 71:171–86. doi: 10.1097/PSY.0b013e3181907c1b. PMID:

  • 267

    FristerASchmidtCSchnebleNBrodhunMGonnertFA. Phosphoinositide 3-kinase γ affects LPS-induced disturbance of blood–brain barrier via lipid kinase-independent control of cAMP in microglial cells. NeuroMol Med. (2014) 16:704–13. doi: 10.1007/s12017-014-8320-z. PMID:

  • 268

    HuYYaoYXieYLiuQHeH. Correlation between systemic immune-inflammatory index and graded diagnosis of periodontitis: a combined cross-sectional and retrospective study. BMC Oral Health. (2024) 24(1):1545. doi: 10.1186/s12903-024-05335-x. PMID:

  • 269

    HenryCJHuangYWynneAHankeMHimlerJ. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflamm. (2008) 5:15. doi: 10.1186/1742-2094-5-15. PMID:

  • 270

    ALHarthiSSBinShabaibMSAlwahibiAGamalSElashiryE. Periodontal and peri-implant status and whole salivary interleukin 1-beta levels among individuals using selective serotonin reuptake inhibitors: an observational study. BMC Oral Health. (2023) 23:310. doi: 10.1186/s12903-023-02908-0. PMID:

  • 271

    FischerLADemerathEBittner-EddyPCostalongaM. Placental colonization with periodontal pathogens: the potential missing link. Am J Obstetrics Gynecology. (2019) 221:383–92:e3. doi: 10.1016/j.ajog.2019.04.029. PMID:

  • 272

    JangHPatoineAWuTTCastilloDAXiaoJ. Oral microflora and pregnancy: a systematic review and meta-analysis. Sci Rep. (2021) 11:16870. doi: 10.1038/s41598-021-96495-1. PMID:

  • 273

    YangIClaussenHArthurRAHertzbergVSGeursN. Subgingival microbiome in pregnancy and a potential relationship to early term birth. Front Cell Infect Microbiol. (2022) 12:873683. doi: 10.3389/fcimb.2022.873683. PMID:

  • 274

    BosshardtDD. The periodontal pocket: pathogenesis, histopathology and consequences. Periodontology 2000. (2018) 76:43–50. doi: 10.1111/prd.12153. PMID:

  • 275

    de JonghCAde VriesTJBikkerFJGibbsSKromBP. Mechanisms of Porphyromonas gingivalis to translocate over the oral mucosa and other tissue barriers. J Oral Microbiol. (2023) 15:2205291. doi: 10.1080/20002297.2023.2205291. PMID:

  • 276

    PignatelliPNuccioFPiattelliACuriaMC. The role of Fusobacterium nucleatum in oral and colorectal carcinogenesis. Microorganisms. (2023) 11:2358. doi: 10.3390/microorganisms11092358. PMID:

  • 277

    LithgowKVBuchholzVCHKuEKonschuhSD'AubeterreA. Protease activities of vaginal Porphyromonas species disrupt coagulation and extracellular matrix in the cervicovaginal niche. NPJ Biofilms Microbiomes. (2022) 8:8. doi: 10.1038/s41522-022-00270-7. PMID:

  • 278

    Vander HaarELSoJGyamfi-BannermanCHanYW. Fusobacterium nucleatum and adverse pregnancy outcomes: epidemiological and mechanistic evidence. Anaerobe. (2018) 50:55. doi: 10.1016/j.anaerobe.2018.01.008. PMID:

  • 279

    GómezLADe AvilaJCastilloDMMontenegroDATrujilloTG. Porphyromonas gingivalis placental atopobiosis and inflammatory responses in women with adverse pregnancy outcomes. Front Microbiol. (2020) 11:591626. doi: 10.3389/fmicb.2020.591626. PMID:

  • 280

    GareJKanouteAMedaNViennotSBourgeoisDCarrouelF. Periodontal conditions and pathogens associated with pre-eclampsia: a scoping review. Int J Environ Res Public Health. (2021) 18:7194. doi: 10.3390/ijerph18137194. PMID:

  • 281

    ChenJLiuFXTaoRX. Relationship between ultrasound parameters of the umbilical and middle cerebral arteries and intrauterine fetal distress. World Journal of Clinical Cases. (2024) 12(16):2745. doi: 10.12998/wjcc.v12.i16.2745

  • 282

    HirohataNKomine‐AizawaSTamuraMOchiaiKSugitaniM. Porphyromonas gingivalis suppresses trophoblast invasion by soluble factors. J Periodontology. (2017) 88:1366–73. doi: 10.1902/jop.2017.170193. PMID:

  • 283

    TavarnaTWolfeBWuXReyesL. Porphyromonas gingivalis-mediated disruption in spiral artery remodeling is associated with altered uterine NK cell populations and dysregulated IL-18 and Htra1. Sci Rep. (2022) 12:14799. doi: 10.1038/s41598-022-19239-9. PMID:

  • 284

    ZhaoSDongYLiYWangZChenYDongY. Melatonin alleviates lipopolysaccharide-induced abnormal pregnancy through MTNR1B regulation of m6A. Int J Mol Sci. (2024) 25:733. doi: 10.3390/ijms25020733. PMID:

  • 285

    Sandoval-ColinDEGodines-EnriquezMSEspejel-NunezABeltrán-MontoyaJJPicazo-MendozaDA. Cervicovaginal cytokines to predict the onset of normal and preterm labor: a pseudo-longitudinal study. Reprod Sci. (2023) 30:221–32. doi: 10.1007/s43032-022-01007-9. PMID:

  • 286

    PresiccePCappellettiMSenthamaraikannanPMaFMorselliM. TNF-signaling modulates neutrophil-mediated immunity at the feto-maternal interface during LPS-induced intrauterine inflammation. Front Immunol. (2020) 11:558. doi: 10.3389/fimmu.2020.00558. PMID:

  • 287

    LiWZhaoXLiSChenXCuiH. Upregulation of TNF-α and IL-6 induces preterm premature rupture of membranes by activation of ADAMTS-9 in embryonic membrane cells. Life Sci. (2020) 260:118237. doi: 10.1016/j.lfs.2020.118237. PMID:

  • 288

    QiHBRanYX. Emphasis on the etiology and pathogenesis of preterm birth syndrome. Chin J Pract Gynecology Obstetrics. (2022) 38:134–7. doi: 10.19538/j.fk2022020102

  • 289

    AllenEMMatthewsJBO’HalloranDJGriffithsHRChappleIL. Oxidative and inflammatory status in Type 2 diabetes patients with periodontitis. J Clin Periodontology. (2011) 38:894–901. doi: 10.1111/j.1600-051X.2011.01764.x. PMID:

  • 290

    PradeepARAgarwalEBajajPRaoNS. 4-Hydroxy-2-nonenal, an oxidative stress marker in crevicular fluid and serum in type 2 diabetes with chronic periodontitis. Contemp Clin Dentistry. (2013) 4:281–5. doi: 10.4103/0976-237X.118342. PMID:

  • 291

    SaglamECanakciCFSebinSOSaruhanNIngecM. Evaluation of oxidative status in patients with chronic periodontitis and polycystic ovary syndrome: A cross‐sectional study. J Periodontology. (2018) 89:76–84. doi: 10.1902/jop.2017.170129. PMID:

  • 292

    SariADavutogluVBozkurtETanerILErciyasK. Effect of periodontal disease on oxidative stress markers in patients with atherosclerosis. Clin Oral Investigations. (2022) 26:1713–24. doi: 10.1007/s00784-021-04144-8. PMID:

  • 293

    DengYXiaoJMaLWangCWangX. Mitochondrial dysfunction in periodontitis and associated systemic diseases: lmplications for pathomechanisms and therapeutic strategies. Int J Mol Sci. (2024) 25:1024. doi: 10.3390/ijms25021024. PMID:

  • 294

    LiuJWangXXueFZhengMLuanQ. Abnormal mitochondrial structure and function are retained in gingival tissues and human gingival fibroblasts from patients with chronic periodontitis. J Periodontal Res. (2022) 57:94–103. doi: 10.1111/jre.12941. PMID:

  • 295

    MarotteHFargePGaudinPAlexandreCMouginB. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheumatic Dis. (2006) 65:905–9. doi: 10.1136/ard.2005.036913. PMID:

  • 296

    LundbergKWegnerNYucel-LindbergTVenablesPJ. Periodontitis in RA—the citrullinated enolase connection. Nat Rev Rheumatol. (2010) 6:727–30. doi: 10.1038/nrrheum.2010.139. PMID:

  • 297

    HendlerAMulliTKHughesFJPerrettDBombardieriM. Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. J Dent Res. (2010) 89:1389–94. doi: 10.1177/0022034510381903. PMID:

  • 298

    ScherJUUbedaCEquindaMKhaninRBuischiY. Periodontal disease and the oral microbiota in new‐onset rheumatoid arthritis. Arthritis Rheumatism. (2012) 64:3083–94. doi: 10.1002/art.34539. PMID:

  • 299

    ManoilDBostanciNMumcuGInancNCanM. Novel and known periodontal pathogens residing in gingival crevicular fluid are associated with rheumatoid arthritis. J Periodontology. (2021) 92:359–70. doi: 10.1002/JPER.20-0295. PMID:

  • 300

    LiuJWangXZhengMLuanQ. Oxidative stress in human gingival fibroblasts from periodontitis versus healthy counterparts. Oral Dis. (2023) 29:1214–25. doi: 10.1111/odi.14103. PMID:

  • 301

    ZhangMJLuanQX. Comparison of salivary 8-OHdG levels among patients with different types of periodontitis. J Oral Sci Res. (2017) 33:898–900. doi: 10.13701/j.cnki.kqyxyj.2017.08.024

  • 302

    EbersoleJLNovakMJMichalowiczBSHodgesJSSteffenMJ. Systemic immune responses in pregnancy and periodontitis: relationship to pregnancy outcomes in the Obstetrics and Periodontal Therapy (OPT) study. J Periodontology. (2009) 80:953–60. doi: 10.1902/jop.2009.080464. PMID:

  • 303

    AkhiRWangCNissinenAEKankaanpaaJBloiguR. Salivary IgA to MAA-LDL and oral pathogens are linked to coronary disease. J Dent Res. (2019) 98:296–303. doi: 10.1177/0022034518818445. PMID:

  • 304

    IskanderMMZLamontGJTanJPisanoMUriarteSM. Tobacco smoke exacerbates Filifactor alocis pathogenicity. J Clin Periodontology. (2023) 50:121–30. doi: 10.1111/jcpe.13729. PMID:

  • 305

    BaillyC. The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products. Japanese Dental Sci Rev. (2020) 56:90–6. doi: 10.1016/j.jdsr.2020.04.002. PMID:

  • 306

    ShiYTHeJMTongZAQianYJWangQW. Ligature-induced periodontitis drives colorectal cancer: an experimental model in mice. J Dent Res. (2023) 102:689–98. doi: 10.1177/00220345231158269. PMID:

  • 307

    MimaKSukawaYNishiharaRQianZRMaiY. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. (2015) 1:653–61. doi: 10.1001/jamaoncol.2015.1377. PMID:

  • 308

    MaekawaTKraussJLAbeTJotwaniRTriantafilouM. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe. (2014) 15:768–78. doi: 10.1016/j.chom.2014.05.012. PMID:

  • 309

    LinJHuangDXuHZhanFTanX. Macrophages: a communication network linking Porphyromonas gingivalis infection and associated systemic diseases. Front Immunol. (2022) 13:952040. doi: 10.3389/fimmu.2022.952040. PMID:

  • 310

    NarikiyoMTanabeCYamadaYIgakiHTachimoriY. Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers. Cancer Sci. (2004) 95:569–74. doi: 10.1111/j.1349-7006.2004.tb02488.x. PMID:

  • 311

    XuCFanLLinYShenWQiY. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. (2021) 13:1980347. doi: 10.1080/19490976.2021.1980347. PMID:

  • 312

    XuanYShiQLiuGJLuanQCaiY. Porphyromonas gingivalis infection accelerates atherosclerosis mediated by oxidative stress and inflammatory responses in ApoE-/- mice. Clin Lab. (2017) 63:1627–37. doi: 10.7754/Clin.Lab.2017.170410. PMID:

  • 313

    JiangSYWeiCCShangTTLianQWuCX. High glucose induces inflammatory cytokine through protein kinase C-induced toll-like receptor 2 pathway in gingival fibroblasts. Biochem Biophys Res Commun. (2012) 427:666–70. doi: 10.1016/j.bbrc.2012.09.118. PMID:

  • 314

    Vieira RibeiroFde MendonçaACSantosVRBastosMFFigueiredoLC. Cytokines and bone‐related factors in systemically healthy patients with chronic periodontitis and patients with type 2 diabetes and chronic periodontitis. J Periodontology. (2011) 82:1187–96. doi: 10.1902/jop.2011.100643. PMID:

  • 315

    SantosVRLimaJAGonçalvesTEDBastosMFFigueiredoLC. Receptor activator of nuclear factor‐kappa B ligand/osteoprotegerin ratio in sites of chronic periodontitis of subjects with poorly and well‐controlled type 2 diabetes. J Periodontology. (2010) 81:1455–65. doi: 10.1902/jop.2010.100125. PMID:

  • 316

    YuSLiHMaYFuY. Matrix metalloproteinase‐1 of gingival fibroblasts influenced by advanced glycation end products (AGEs) and their association with receptor for AGEs and nuclear factor‐κB in gingival connective tissue. J Periodontology. (2012) 83:119–26. doi: 10.1902/jop.2011.100754. PMID:

  • 317

    SorciGRiuzziFGiambancoIDonatoR. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta (BBA)-Molecular Cell Res. (2013) 1833:101–9. doi: 10.1016/j.bbamcr.2012.10.021. PMID:

  • 318

    RubinsteinMRWangXLiuWHaoYCaiG. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. (2013) 14:195–206. doi: 10.1016/j.chom.2013.07.012. PMID:

  • 319

    YilmazOJungasTVerbekePOjciusDM. Activation of the phosphatidylinositol 3-kinase/Akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis. Infect Immun. (2004) 72:3743–51. doi: 10.1128/iai.72.7.3743-3751.2004. PMID:

  • 320

    MoffattCELamontRJ. Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect Immun. (2011) 79:2632–7. doi: 10.1128/iai.00082-11. PMID:

  • 321

    ChangCWangHLiuJPanCZhangD. Porphyromonas gingivalis infection promoted the proliferation of oral squamous cell carcinoma cells through the miR-21/PDCD4/AP-1 negative signaling pathway. ACS Infect Dis. (2019) 5:1336–47. doi: 10.1021/acsinfecdis.9b00032. PMID:

  • 322

    KuoPJTuHPChinYTLuSHChiangCY. Cyclosporine‐A inhibits MMP‐2 and‐9 activities in the presence of Porphyromonas gingivalis lipopolysaccharide: an experiment in human gingival fibroblast and U937 macrophage co‐culture. J Periodontal Res. (2012) 47:431–8. doi: 10.1111/j.1600-0765.2011.01450.x. PMID:

  • 323

    InabaHSugitaHKuboniwaMIwaiSHamadaM. Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of pro MMP 9 and its activation. Cell Microbiol. (2014) 16:131–45. doi: 10.1111/cmi.12211. PMID:

  • 324

    SunCHLiBBWangBZhaoJZhangXY. The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management. Chronic Dis Trans Med. (2019) 5:178–87. doi: 10.1016/j.cdtm.2019.09.001. PMID:

  • 325

    GurCIbrahimYIsaacsonBYaminRAbedJ. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. (2015) 42:344–55. doi: 10.1016/j.immuni.2015.01.010. PMID:

  • 326

    RenJLHanXLohnerHHoyleRGLiJ. P. gingivalis infection upregulates PD-L1 expression on dendritic cells, suppresses CD8+ T-cell responses, and aggravates oral cancer. Cancer Immunol Res. (2023) 11:290–305. doi: 10.1158/2326-6066.CIR-22-0541. PMID:

  • 327

    YoshidaKYoshidaKSeyamaMHiroshimaYMekataM. Porphyromonas gingivalis outer membrane vesicles in cerebral ventricles activate microglia in mice. Oral Dis. (2023) 29:3688–97. doi: 10.1111/odi.14413. PMID:

  • 328

    IshikawaMYoshidaKOkamuraHOchiaiKTakamuraH. Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the Akt/GSK-3β signaling pathway. Biochim Biophys Acta (BBA)-Molecular Basis Dis. (2013) 1832:2035–43. doi: 10.1016/j.bbadis.2013.07.012. PMID:

  • 329

    SuhJSKimSBoströmKIWangCYKimRH. Periodontitis-induced systemic inflammation exacerbates atherosclerosis partly via endothelial–mesenchymal transition in mice. Int J Oral Sci. (2019) 11:21. doi: 10.1038/s41368-019-0054-1. PMID:

  • 330

    YangWWGuoBJiaWYJiaY. Porphyromonas gingivalis‐derived outer membrane vesicles promote calcification of vascular smooth muscle cells through ERK1/2‐RUNX 2. FEBS Open Bio. (2016) 6:1310–9.

  • 331

    SalminenAHyvärinenKRitariJCaetanoAKamburO. Genetic loci associated with periodontitis: the finngen study based on national health registers. J Clin Periodontology. (2025) 52:1263–75. doi: 10.1111/jcpe.14193. PMID:

  • 332

    NibaliLStephenASAllakerRPDi PinoATerranovaV. Associations between host genetic variants and subgingival microbiota in patients with the metabolic syndrome. Int J Mol Sci. (2023) 24:16649. doi: 10.3390/ijms242316649. PMID:

  • 333

    LehmannK. Oral Porphyromonas gingivalis infection induces epigenetic changes that promote persistence of cardiovascular disease risk [MSc thesis]. Edmonton (AB): University of Alberta. (2020) 211 p. doi: 10.7939/R3-1YJT-EN58

  • 334

    LiXWangHYuXSahaGKalafatiL. Maladaptive innate immune training of myelopoiesis links inflammatory comorbidities. Cell. (2022) 185:1709–27:e18. doi: 10.1016/j.cell.2022.03.043. PMID:

  • 335

    ZhangELWuYJ. Metabolic memory: mechanisms and implications for diabetic vasculopathies. Sci China Life Sci. (2014) 57:845–51. doi: 10.1007/s11427-014-4710-6. PMID:

  • 336

    KonigMFAbuslemeLReinholdtJPalmerRJTelesRP. Aggregatibacter actinomycetemcomitans–induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med. (2016) 8:369ra176–369ra176. doi: 10.1126/scitranslmed.aaj1921. PMID:

  • 337

    EstellerM. Epigenetics in cancer. N Engl J Med. (2008) 358:1148–59. doi: 10.1056/nejmra072067. PMID:

  • 338

    Parada VenegasDDe la FuenteMKLandskronGGonzálezMJQueraR. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. (2019) 10:277. doi: 10.3389/fimmu.2019.00277. PMID:

  • 339

    PerriRNaresSZhangSBarrosSPOffenbacherS. MicroRNA modulation in obesity and periodontitis. J Dent Res. (2012) 91:33–8. doi: 10.1177/0022034511425045. PMID:

  • 340

    NaqviARBrambilaMFMartínezGChapaGNaresS. Dysregulation of human miRNAs and increased prevalence of HHV miRNAs in obese periodontitis subjects. J Clin Periodontology. (2019) 46:51–61. doi: 10.1111/jcpe.13040. PMID:

  • 341

    RodriguezNMLorenPPaezIMartínezCChaparroA. MicroRNAs: the missing link between hypertension and periodontitis? Int J Mol Sci. (2024) 25:1992. doi: 10.3390/ijms25041992. PMID:

  • 342

    MatulieneGStuderRLangNPSchmidlinKPjeturssonBE. Significance of periodontal risk assessment in the recurrence of periodontitis and tooth loss. J Clin Periodontology. (2010) 37:191–9. doi: 10.1111/j.1600-051X.2009.01508.x. PMID:

  • 343

    LeowNMMorenoFMarlettaDHussainSBButiJ. Recurrence and progression of periodontitis and methods of management in long‐term care: a systematic review and meta‐analysis. J Clin Periodontology. (2022) 49:291–313. doi: 10.1111/jcpe.13553. PMID:

  • 344

    MagnussonIWalkerCB. Refractory periodontitis or recurrence of disease. J Clin Periodontology. (1996) 23:289–92. doi: 10.1111/j.1600-051x.1996.tb02091.x. PMID:

  • 345

    BreivikTGundersenYMyhrerTFonnumFOsmundsenH. Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti‐depressant tianeptine. J Clin Periodontology. (2006) 33:469–77. doi: 10.1111/j.1600-051X.2006.00935.x. PMID:

  • 346

    Brancode AlmeidaLSFrancoGCNCastroMLVieiraMSGalvao-MoreiraLV. Protective effects of desipramine on alveolar bone in experimental periodontitis. J Periodontology. (2020) 91:1694–703. doi: 10.1002/JPER.19-0569. PMID:

  • 347

    BhatiaASharmaRKTewariSKhuranaHNarulaSC. Effect of fluoxetine on periodontal status in patients with depression: a cross‐sectional observational study. J Periodontology. (2015) 86:927–35. doi: 10.1902/jop.2015.140706. PMID:

  • 348

    AnTChenYLiMLiuYZhangZ. Inhibition of experimental periodontitis by a monoclonal antibody against porphyromonas gingivalis HA2. Microb Pathogen. (2021) 154:104633. doi: 10.1016/j.micpath.2020.104633. PMID:

  • 349

    WeiXQianSYangYMoJ. Microbiome‐based therapies for periodontitis and peri‐implantitis. Oral Dis. (2024) 30:2838–57. doi: 10.1111/odi.14782. PMID:

  • 350

    BargerSWHarmonAD. Microglial activation by alzheimeramyloid precursor protein and modulation by apolipoproteinE. Nature. (1997) 388:878–81. doi: 10.1038/42257. PMID:

  • 351

    IzuiSSekineSMuraiHTakeuchiHAmanoA. Inhibitory effects of curcumin against cytotoxicity of porphyromonas gingivalis outer membrane vesicles. Arch Oral Biol. (2021) 124:105058. doi: 10.1016/j.archoralbio.2021.105058. PMID:

  • 352

    XuanYGaoYHuangHWangXCaiY. Tanshinone I1A attenuates atherosclerosis in apolipoprotein E knockout mice infected with porphyromonas gingivalis. Inflammation. (2017) 40:1631–42. doi: 10.1007/s10753-017-0603-8. PMID:

  • 353

    YoshinoNIkedaTNakaoR. Dual inhibitory activity of petroselinic acid enriched in fennel against porphyromonas gingivalis. Front Microbiol. (2022) 13:816047. doi: 10.3389/fmicb.2022.816047. PMID:

  • 354

    CantleyMDFairlieDPBartoldPMRainsfordKDLeGT. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol. (2011) 226:3233–41. doi: 10.1002/jcp.22684. PMID:

  • 355

    ZhangZYSchluesenerHJ. HDAC inhibitor MS‐275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. Prostate. (2012) 72:90–9. doi: 10.1002/pros.21410. PMID:

  • 356

    NibaliLDonosNTerranovaVAntoninoDPSalvatoreDM. Left ventricular geometry and periodontitis in patients with the metabolic syndrome. Clin Oral Investigations. (2019) 23:2695–703. doi: 10.1007/s00784-018-2667-8. PMID:

Summary

Keywords

immune dysregulation, inflammatory overflow, oral - X axis, oral pathogens, oxidative stress

Citation

Jin W, Tang L, Yang J, Hu X, Guo W, Ai H, Zuo Y and Jin Z (2026) The oral - X axis: from periodontal dysbiosis to systemic disease. Front. Immunol. 17:1806445. doi: 10.3389/fimmu.2026.1806445

Received

07 February 2026

Revised

06 April 2026

Accepted

08 April 2026

Published

29 April 2026

Volume

17 - 2026

Edited by

Xuekun Fu, Southern University of Science and Technology, China

Reviewed by

Lorenzo Malatino, Cannizzaro Hospital, Italy

Zureya Fontes, Universidad Autonoma de Baja California Facultad de Odontologia Mexicali, Mexico

Updates

Copyright

*Correspondence: Yuling Zuo, ; Zhao Jin,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics